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ABSTRACT
Interleukin-2 (IL-2) is an immunomodulatory cytokine that is clinically relevant for the
treatment of metastatic renal cell carcinoma and melanoma. The primary objective of the
research presented in this thesis was to generate IL-2 mutants with potentially improved
therapeutic effectiveness. Based on qualitative considerations and simple mathematical
modeling, we hypothesized that IL-2 mutants with increased affinity for the alpha subunit
of the IL-2 receptor (IL-2Rct) would have increased potency for proliferation of activated
T cells and hence potentially improved therapeutic value. Yeast surface display and
directed evolution were used to generate a class of IL-2 mutants with enhanced IL-2Ra
affinity. In a novel pulsed bioassay designed to approximate the rapid systemic clearance
pharmacokinetics of IL-2, these mutants exhibit significantly increased potency for T cell
proliferation, thus validating our hypothesis. Our results underscore the critical nature of
the choice of appropriate bioassays to evaluate engineered proteins and other drugs.
Conventional bioassays not only fail to reveal the increased potency resulting from
enhanced IL-2Ra affinity (false negatives), but also suggest improved potency for a
mutant without enhanced activity in the pulsed bioassay (false positive).
Cell-surface IL-2Ra acts as a ligand reservoir for the IL-2 mutants, leading to increased
cell-surface persistence of the IL-2 mutants with increased IL-2Ra affinity and
consequently increased integrated growth signal. This is analogous to the prolonged
persistence of IL-15 on cell surface IL-15Rac reservoirs. IL-2 and IL-15 signal through
the IL-2RP and IL-2Ry subunits while each have a private non-signaling alpha receptor
subunit. IL-15 has a high affinity (Kd ~ 10pM) for its private alpha receptor subunit,
unlike wild-type IL-2 (Kd ~ 10 nM). IL-2 mutants with picomolar affinity for IL-2Ra
stimulate T cell growth responses quantitatively equivalent to those mediated by IL-15.
Our results suggest that the contrasting effects of IL-2 and IL-15 on T cells in vivo are
largely due to the 1,000-fold different affinities of wild-type IL-2 and IL-15 for their
respective private alpha receptor subunits.
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Chapter 1: INTRODUCTION AND BACKGROUND
Cytokines are low molecular weight proteins that regulate the complex interactions
between cells in the immune systems. Cytokines bind to receptors on the cell surface of
target cells and mediate diverse biological responses such as proliferation, differentiation,
cell motility or death. Interleukin-2 (IL-2), originally identified as a T cell growth factor
(Gillis et al., 1978), is one of the most widely studied cytokines.
IL-2 is a variably glycosylated 15-18 kDa protein consisting of 133 amino acids that
exerts a variety of immunoregulatory effects via specific cell surface receptors on
different cell types (Probst et al., 1995). These include activation and expansion of
lymphocyte subsets, including T helper cells, cytotoxic and suppressor cells, B cells,
natural killer (NK) cells, as well as cytotoxic macrophages. Specifically, the proliferation
of activated T cells and CD56 bright NK cells caused by IL-2 (Fehniger et al., 2002) has
been exploited in the treatment of metastatic renal cell carcinoma and melanoma (Atkins
et al., 1999; Fyfe et al., 1995). The goal of the research presented in this thesis is to
generate IL-2 mutants with potentially improved therapeutic effectiveness.
1.1 The IL-2 Receptor
The biological activity of IL-2 is mediated through a multi-subunit IL-2 receptor complex
(IL-2R), previously reviewed in (Nelson and Willerford, 1998). The IL-2 receptor is
composed of three cell-surface subunits: p55 (IL-2Ra), p75 (IL-2RP) and p64 (IL-2Ry),
which span the cell membrane. IL-2Ra (also known as Tac antigen or CD125) is
a - 55kDa protein with a 219 amino acid extracellular domain, a transmembrane domain
of 19 amino acid residues and a short cytoplasmic domain with only thirteen residues.
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IL-2Ra is highly homologous to the alpha chain of the IL-15 receptor. IL-2RP (also
known as CD122) is a -75 kDa protein with an extracellular domain having 214 residues,
a 25 residue transmembrane domain and a large cytoplasmic domain of 286 residues.
IL-2RP3 exhibits homology with several other receptors of the hematopoetic receptor
superfamily. The chain of the IL-2 receptor is shared with IL-15. IL-2Ry (CD132) is a
-64 kDa protein having an extracellular domain with 232 residues, a transmembrane
domain with 29 residues and 86 residues in the cytoplasmic domain. IL-2Ry is also called
the yc receptor (y-common) as it is shared with IL-4, IL-7, IL-9 and IL-15.
The expression of the IL-2 receptor subunits on different cell types has been previously
reviewed (Nelson and Willerford, 1998). It must be noted that conflicting data exists in
the literature concerning the expression the three IL-2R subunits on peripheral blood
mononuclear cells. This is possibly due to the sensitivity of receptor expression to the
conditions of the blood sample analyzed (David et al., 1998). We restrict our discussion
here to cell types that mediate the beneficial and deleterious effects in IL-2 based therapy.
The expression of the a subunit is upregulated by T cells upon antigen activation, and is
found in - 100-fold excess over IL-2RP and IL-2Ry on the surface of activated T cell
populations (Lowenthal and Greene, 1987). IL-2Ra is also expressed on a subset of NK
cells that have high levels of expression of the CD56 antigen (CD56 bright NK cells).
Both CD56 bright and CD56 dim (with low levels of CD56 expression) NK cells express
IL-2RP and IL-2Ry (Fehniger et al., 2002).
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1.2 IL-2 interactions with receptor subunits
IL-2 binds the IL-2Rc4ay trimeric complex with high affinity (Kd- 10 pM) (Nelson and
Willerford, 1998). IL-2 interacts directly with each subunit in the high affinity (afry)
complex. IL-2 binds IL-2Ra with low affinity (Kd - 10 nM) and IL-2R with very low
affinity (Kd 100 nM). IL-2Ry, on the other hand, binds IL-2 with barely measurable
binding affinity. Surface plasmon resonance studies with the soluble extracellular domain
of IL-2Ry indicate the Kd of this interaction is in the micromolar range (Liparoto et al.,
2002). IL-2Ra and IL-2RP, when co-expressed, form a pseudo-high affinity complex
capable of binding IL-2, (K ~ 30 pM). IL-2R1 and IL-2Ry can associate in a
ligand-dependent fashion to form the IL-2RPy complex that binds IL-2 with intermediate
affinity (Kd 1 nM). Thus, the binding of IL-2 to its receptor subunits is modular and
cooperative. Fluorescence resonance energy transfer (FRET) studies on a T cell line
indicate that the IL-2 receptor subunits are co-localized on the cell surface (Damjanovich
et al., 1997). The most likely mechanism for the binding of IL-2 to its receptor subunits
involves the initial binding of IL-2 to pre-associated IL-2Ra and IL-2RP and subsequent
recruitment of IL-2Ry to the complex (Nelson and Willerford, 1998).
1.3 IL-2 mediated signaling
IL-2 mediated signal transduction through the IL-2 receptor complex has been previously
reviewed (Gaffen, 2001; Nelson and Willerford, 1998). IL-2RP and IL-2Ry associate in a
ligand-dependent fashion and form the signaling complex (Nakamura et al., 1994).
IL-2Ra displays no ability to transduce intracellular signals. This is most likely due to the
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short cytoplasmic region of IL-2Ra. However, IL-2Ra on one cell can present IL-2 to
IL-2Ry on an adjacent cell and enhance IL-2 signaling (Eicher and Waldmann, 1998).
Heterodimerization of IL-2R3 and IL-2Ry activates the Jak3 tyrosine kinase associated
with IL-2Ry. Jak3 is responsible for the initial phosphorylation of IL-2RP, initiating the
recruitment of several signal-transducing molecules to the cytoplasmic tail of IL-2R3,
such as Jakl, STAT5 and STAT3, the Shc-adaptor protein, Syk and p561ck. These events
result in the activation of the Jak/STAT, phosphatidylinositol 3-kinase and
ras/rafl/mitogen-activated protein kinase pathways (Yu et al., 2000). IL-2 signaling is
linked to the increased expression of the proto-oncogenes c-fos/c-jun and c-myc and the
anti-apoptotic gene bcl-2. IL-2 is also implicated in Activation Induced Cell Death of
activated T cells through the Fas-FasL apoptotic pathway (Gaffen, 2001; Nelson and
Willerford, 1998). The IL-2Ry signals are essential for cell survival. This is because
IL-2Ry is crucial for the Jak3 phosphorylation of IL-2RP and hence the subsequent
events that follow this. Decreased IL-2Ry due to receptor downregulation leads to
lowered expression of the bc1-2 gene. This drives the T cells to apoptosis in vivo (Li et
al., 2001).
1.4 IL-2R mediated trafficking
T-cell lines degrade exogenous IL-2 with a half-life (t,,2) of 60-80 minutes, following
addition of saturating amounts of ligand (Fujii et al., 1986). This is due to receptor-
mediated internalization and degradation of IL-2. IL-2Ra alone cannot induce
internalization, but IL-2/IL-2RIy and the IL-2/IL-2Rapy complexes are endocytosed
with a t, 2 of 10-15 minutes (Chang et al., 1996; Gullberg, 1987). The internalization of
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the IL-2/IL-2R complex occurs through a mechanism that is likely to be distinct from
endocytosis mediated by clathrin-coated structures (Subtil et al., 1994). Within ten
minutes of internalization, IL-2 remains bound to a, and y in early endosomes. The
components of IL-2-IL-2R complex undergo differential sorting wherein IL-2Ra is
recycled to the cell surface, while IL-2 associated with IL-2RPy is routed to the lysosome
and degraded (Fallon and Lauffenburger, 2000). The sorting of IL-2Ry to the lysosome
is mediated by an alpha helical signal on the cytoplasmic domain of IL-2RP (Subtil et al.,
1997). In the absence of receptor synthesis, the half-life of IL-2RP and IL-2Ry is 1 hr,
while IL-2Rca has a half-life of - 48 hrs (Hemar et al., 1995). Thus IL-2/IL-2R trafficking
results in degradation of IL-2, IL-2RP and IL-2Ry and downregulation of the high affinity
IL-2R.
Different motifs on the cytoplasmic and transmembrane domains of IL-2RP may act as
weak signals that additively mediate internalization (Subtil and Dautry-Varsat, 1998).
Mutational studies on the IL-2R subunits also indicate an important role for IL-2Ry for
internalization of IL-2. Rapid IL-2 internalization has been observed for T cells
expressing IL-2Rct and IL-2Ry (Morelon and Dautry-Varsat, 1998). There is evidence to
suggest that there exist distinct cytoplasmic regions of IL-2Ry function during
endocytosis, one for ligand-independent constitutive endocytosis of IL-2Ry and another
for IL-2Ry dependent IL-2 induced endocytosis (Yu et al., 2000). The IL-2R system
exhibits modularity in signaling and trafficking events, in addition to IL-2 binding.
Signaling impaired mutants of IL-2Ry that can still contribute to receptor-mediated
internalization have been identified. A mutant form of IL-2Ry, which exhibits impaired
11
endocytosis, despite normal IL-2 induced signaling, has also been identified (Yu et al.,
2000).
1.5 IL-2 based therapy
IL-2 based therapies exploit the proliferation of antigen-activated T cells and CD56
bright NK cells caused by IL-2 (Fehniger et al., 2002), for treatment of metastatic renal
cell carcinoma and melanoma (Atkins et al., 1999; Fyfe et al., 1995). Low doses of IL-2
have been shown to enhance immune function in HIV positive individuals (Jacobson et
al., 1996). However, a narrow therapeutic window has hampered IL-2 therapies:
undesirable inflammatory responses are activated at IL-2 concentrations above 100 pM
through stimulation of CD56 dim NK cells (Fehniger et al., 2002) while stimulation of T
cells is not achieved below 1 pM. When administered intravenously, IL-2 is rapidly
cleared from the body. IL-2 serum concentrations are in the nanomolar range initially,
and fall rapidly with a double exponential clearance rate with half-lives of 12.9 and 85
minutes respectively (Konrad et al., 1990). Thus it is difficult to maintain the
therapeutically effective serum concentration range (1 - 100 pM) over a sustained period
of time. This narrow therapeutic window of effective concentration coupled with rapid
systemic clearance adversely affects IL-2 therapy. An improved IL-2 variant with an
enhanced therapeutic window would greatly impact IL-2 based therapies.
1.6 Thesis Overview
The primary objective of this thesis was to generate IL-2 mutants with potentially
improved therapeutic value. Hypothesis-driven directed evolution was used towards this
end. A directed evolution approach involves the generation of protein variants with
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desired properties through multiple rounds of mutation and selection. A hypothesis
linking the effect of altered binding affinity of the IL-2/ IL-2 receptor interaction on the
cellular and systemic biological effects mediated by IL-2 was formulated based on
existing data in literature. IL-2 mutants with suitably altered receptor binding affinities
were generated by directed evolution and found to have improved biological properties in
carefully designed bioassays. Our approach is distinct from a directed evolution approach
that seeks to directly find protein variants with improved biological property without
linking biophysical properties of the protein to biological activity. Examples of this direct
approach include directed evolution to improve the potency of IL-12 to cause T cell
proliferation (Leong et al., 2003) and engineering human interferon gamma to obtain
variants with improved antiviral activity (Chang et al., 1999).
1.6.1 Hypothesis generation
Activated T cells and CD56 bright NK cells, which express IL-2Ra, mediate the
beneficial effects of IL-2 while CD56 dim NK cells that do not express IL-2Ra are
involved in the deleterious effects of IL-2 (Fehniger et al., 2002). On the basis of
mathematical modeling and qualitative considerations detailed in subsequent chapters, we
hypothesized that IL-2 mutants with increased IL-2Ra affinity would have potentially
increased therapeutic effectiveness.
1.6.2 Molecular bioengineering by directed evolution
Display technologies such as phage display (Parmley and Smith, 1988) and yeast surface
display (Boder and Wittrup, 2000), are powerful tools that link genotype to phenotype
can be used for screening large libraries of protein variants for altered binding properties.
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Interleukin-2 mutants with desired physical properties were generated using yeast surface
display and directed evolution. The protein of interest is expressed or "displayed" as a
fusion to a yeast cell surface protein Aga2p (Boder and Wittrup, 1997), as shown in
Figure 1-1. Immunofluorescent labeling of epitope tags can be used to detect the presence
of protein on the yeast cell surface. The surface displayed protein can bind to a soluble
binding partner, in this case soluble IL-2Ra.
The procedure used to select IL-2 mutants with increased affinity for IL-2Ra is illustrated
in Figure 1-2. A library of yeast displayed IL-2 mutants is generated. Each yeast cell
expresses -50000 copies of a single IL-2 mutant on the cell surface. Cells are labeled
with fluorescently tagged soluble IL-2Ra. Yeast cells displaying mutants with improved
binding to IL-2Ra are labeled to a greater extent than cells displaying wild-type IL-2.
Quantitative screening by flow cytometry is used to isolate these yeast displayed IL-2
mutants with desired binding properties (Boder and Wittrup, 2000). After few rounds of
sorting, a pool of yeast-displayed IL-2 mutants with increased affinity for IL-2Ra is
obtained. DNA from the individual clones is isolated and sequenced to establish the
identity of these high IL-2Rat binding IL-2 variants.
Variants with enhanced receptor binding affinities have been isolated for human growth
hormone (Lowman et al., 1991), interleukin-6 (Toniatti et al., 1996) and ciliary
neutrotrophic growth factor (Saggio et al., 1995), using phage display. IL-2 has been
functionally displayed on phage (Buchli et al., 1997), but improved mutants have not
previously been engineered by phage display.
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1.6.3 Validation of hypothesis
The engineered IL-2 mutants were expressed solubly and improved binding to IL-2Ra
was verified in a physiological context - on T cells expressing IL-2Ra. Carefully
designed bioassays that mimic bolus pharmacokinetics were used to evaluate biological
response of T cells to the engineered IL-2 mutants. In these assays, the mutants exhibit
significantly higher activity than wild-type IL-2, indicating potentially improved
therapeutic value. The IL-2 mutants also enable us to formulate a quantitative relationship
between receptor-ligand molecular interactions and biological activity and understand
better the differences between IL-2 and IL-15.
1.6.4 Thesis layout
Chapter 2 describes the generation of the IL-2 mutants with increased affinity for
IL-2Raand preliminary evaluation of the biological activity of these mutants. In
Chapter 3, the design of novel bioassays that mimic bolus pharmacokinetics and the
significantly improved activity of IL-2 mutants in these bioassays are discussed. This
chapter also describes the mechanism leading to improved activity of the IL-2 mutants.
Chapter 4 describes the further construction of a series of high IL-2Rca IL-2 mutants that
are quantitatively equivalent to IL-15 in terms of T cell growth response generated. This
chapter discusses the quantitative relationship between binding affinity and biological
activity for IL-2 and IL-15 and the reasons for the vastly different biological responses
mediated by IL-2 and IL-15. The final chapter discusses the conclusions of this study,
perspectives on the broader applicability of the approach taken and suggested future
work.
15
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Figure 1-1: Yeast Surface Display of IL-2
IL-2 is expressed as a fusion to the yeast cell surface Aga2 protein.
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Chapter 2: INTERLEUKIN-2 MUTANTS WITH ENHANCED
a-RECEPTOR SUBUNIT BINDING AFFINITY
Stimulation of T-cells by IL-2 has been exploited for treatment of metastatic renal
carcinoma and melanoma. However, a narrow therapeutic window delimited by
negligible stimulation of T-cells at low picomolar concentrations and undesirable
stimulation of NK cells at nanomolar concentrations hampers IL-2 based therapies. We
hypothesized that increasing the affinity of IL-2 for IL-2Ra may create a class of IL-2
mutants with increased biological potency as compared to wild-type IL-2. Towards this
end, we have screened libraries of mutated IL-2 displayed on the surface of yeast, and
isolated mutants with a 15-30-fold improved affinity for the IL-2Ra subunit. These
mutants do not exhibit appreciably altered bioactivity at 0.5-5 pM in steady-state
bioassays, concentrations well below the IL-2Ra equilibrium binding constant for both
the mutant and wild-type IL-2. A mutant was serendipitously identified that exhibited
somewhat improved potency, perhaps via altered endocytic trafficking mechanisms
described previously
2.1 Introduction
Interleukin-2 (IL-2) (Theze et al., 1996) is a 133-amino-acid cytokine that induces
proliferation of antigen-activated T-cells and stimulation of NK cells. The proliferation of
T-cells stimulated by IL-2 has been exploited for treatment of metastatic renal carcinoma
and melanoma (Atkins et al., 1999; Fyfe et al., 1995). However, a narrow therapeutic
window has hampered IL-2 therapies: undesirable inflammatory responses are activated
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at IL-2 concentrations above 100 pM through stimulation of NK cells (Jacobson et al.,
1996; Smith, 1993) while stimulation of T cells is not achieved below 1 pM. Given the
very rapid systemic clearance of IL-2 (an initial clearance phase with a half-life of 12.9
min followed by a slower phase with a half-life of 85 min, (Konrad et al., 1990)), it is
difficult to maintain therapeutic concentrations of IL-2 (1-100 pM) for a sustained period.
The biological activity of IL-2 in activated T cells is mediated through a multi-subunit
IL-2 receptor complex (IL-2R) consisting of three cell-surface subunits: p55 (IL-2Ra),
p75 (IL-2RP) and p64 (IL-2Ry), which span the cell membrane (Nelson and Willerford,
1998). NK cells in general express only the IL-2RP and IL-2Ry subunits (Voss et al.,
1992), so enhanced affinity for IL-2Ra might be expected to increase the specificity of
IL-2 for activated T cells relative to NK cells. Manipulation of the binding affinities to
these receptor subunits might be used to alter the biological response to IL-2 and
potentially create an improved therapeutic. Screening of over 2600 IL-2 variants created
by combinatorial cassette mutagenesis has led to the isolation of an IL-2 variant (L18M,
L19S) with increased potency (Berndt et al., 1994). Site-directed mutagenesis was also
utilized to isolate IL-2 variants causing reduced stimulation of NK cells via reduced
binding to IL-2RP and IL-2Ry (Shanafelt et al., 2000).
Display technologies such as phage display (Parmley and Smith, 1988) and yeast surface
display (Boder and Wittrup, 2000), are powerful tools that can be used for screening large
libraries of protein variants for altered binding properties. Variants with enhanced
receptor binding affinities have been isolated for human growth hormone (Lowman et al.,
1991), interleukin-6 (Toniatti et al., 1996) and ciliary neutrotrophic growth factor (Saggio
et al., 1995), using phage display. IL-2 has been functionally displayed on phage (Buchli
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et al., 1997), but improved mutants have not previously been engineered by phage
display.
Here we present IL-2 engineering by directed evolution with yeast surface display, to
generate mutants with increased affinity for IL-2Ra. This is the first reported affinity
maturation of IL-2 for a receptor subunit. T-cell response to IL-2 depends on the number
of IL-2R occupied by IL-2 via: 1) the concentration of IL-2; 2) the number of IL-2R
molecules on the cell surface; and 3) the number of IL-2R occupied by IL-2, i.e. the
affinity of binding interaction between IL-2 and IL-2R (Smith, 1995). Increasing the
affinity of IL-2 for IL-2Ra at the cell surface will increase receptor occupancy within a
limited range of IL-2 concentration, as well as raise the number of IL-2 molecules
localized at the cell surface. The IL-2-IL-2R complex is internalized upon ligand binding
and the different components undergo differential sorting (Hemar et al., 1995). IL-2Ra is
recycled to the cell surface, while IL-2 associated with the IL-2-IL-2Rfy complex is
routed to the lysosome and degraded. Increasing the affinity of IL-2 for IL-2Ra may shift
trafficking of internalized IL-2 towards recycling, causing decreased degradation of IL-2
and hence favorably affect T-cell response (Fallon et al., 2000). Further, IL-2-IL-2Rca on
one cell can augment IL-2 signaling on another cell (Eicher and Waldmann, 1998). IL-15,
which exhibits picomolar binding affinity for its private IL-2Ra subunit, also performs
such juxtacrine signaling (Dubois et al., 2002). Thus, it is conceivable that increasing the
affinity of IL-2 for IL-2Ra may create a class of IL-2 mutants with increased biological
potency as compared to wild-type IL-2. However, in the steady-state bioassays reported
here, a 15-30-fold increase in IL-2Ra binding affinity does not contribute to improved
IL-2 potency.
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2.2 Materials and methods
2.2.1 Yeast surface display of IL-2
The IL-2 gene was subcloned into the pCT302 backbone at Nhel and BamHI restriction
sites. A serine was introduced at position 125 by site directed mutagenesis to obtain what
will be termed "wild-type" C125S IL-2 (equivalent to ProleukinT M). This vector is termed
pCTIL-2.
IL-2 was expressed as an Aga2p protein fusion in Saccharomyces cerevisiae EBY100
transformed with vector pCT-IL-2, by induction in medium containing galactose (Boder
and Wittrup, 1997). A haemagglutinin (HA) epitope tag is expressed N-terminal to IL-2,
while a c-myc epitope tag is attached to the C-terminus of Aga2p-IL-2 fusion. The HA
epitope tag can be detected using immunofluorescent staining using a mouse monoclonal
antibody (mAb) 12CA5 (Roche Molecular Biochemicals) along with a goat anti-mouse
antibody conjugated with Fluorescein Isothiocyanate (FITC). The c-myc epitope tag can
be detected using a mouse monoclonal antibody (mAb) 9el0 (Covance) and a goat anti-
mouse antibody conjugated with FITC. Detection of the c-myc epitope tag at the C-
terminus of the Aga2p-IL-2 fusion is indicative of display of the full length IL-2 fusion
on the yeast cell surface. Yeast cells were labeled with MAb 9el0 as described (Boder
and Wittrup, 2000), to detect the presence of IL-2 fusions on the yeast cell surface
A soluble ectodomain of IL-2Ra (Wu et al., 1999), expressed in insect cell culture, was
purified and biotinylated. Yeast cells were labeled with biotinylated soluble IL-2Ra as
described (Boder and Wittrup, 2000), Labeling with soluble IL-2Ra is indicative of the
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IL-2 fusion on the yeast surface being functional. Yeast displaying an irrelevant single
chain antibody (scFv), D1.3, was used as a negative control.
2.2.2 Construction and screening of IL-2 library
The wild-type IL-2 coding sequence was subjected to random mutagenesis by error-prone
polymerase chain reaction (PCR). The error rate was controlled by varying cycles of PCR
amplification in the presence of nucleotide analogs 8-oxodGTP and dPTP (Zaccolo and
Gherardi, 1999; Zaccolo et al., 1996). The PCR product obtained was further amplified
by PCR without the nucleotide analogs. The final PCR product was transformed into
yeast along with linearized pCT-IL-2. Homologous recombination in vivo in yeast
between the 5' and 3' flanking 50 base pairs of the PCR product with the gapped plasmid
resulted in a library of approximately 5x106 IL-2 variants (Raymond et al., 1999).
Detailed protocols for screening yeast polypeptide libraries have been described (Boder
and Wittrup, 2000). Yeast cells from the IL-2 library were labeled with biotinylated
soluble IL-2Ra at a concentration of 0.2-0.8 nM and saturating concentration of mAb
12CA5 against the HA epitope tag, at 370 C, for 30 min- lhr. Labeling with an antibody
against one of the epitope tags is necessary to normalize for the number of IL-2 fusions
on the yeast surface. The cells were washed, labeled with streptavidin conjugated with
R-phycoerythrin (PE) (Pharmingen) and a goat anti-mouse antibody conjugated with
FITC. The cells were then sorted on the Cytomation Moflo (first two sorts) or the
Beckton Dickinson FACStar flow cytometer to isolate clones with improved binding to
soluble IL-2Ra, relative to wild-type IL-2. Four rounds of sorting by flow cytometry,
were carried out, with regrowth and reinduction of surface expression between each sort,
After the fourth sort, DNA from twenty individual clones was extracted using the
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Zymoprep kit (Zymo Research corporation). The DNA was amplified by transforming
into XL-1 Blue cells (Stratagene). Sequences of the IL-2 mutants were determined by
DNA sequencing.
IL-2 mutants isolated by flow cytometry were subcloned into secretion vectors, and
secreted in yeast shake flask cultures, with an N-terminal FLAG epitope tag and a
C-terminal c-myc epitope tag. The mutants were purified by FLAG immunoaffinity
chromatography (Sigma). Quantification of IL-2 concentration was performed using
quantitative western blotting, with a FLAG-BAP protein standard (Sigma) and mutant
M6 as standards. The stock protein concentrations obtained were 11.7±1.2 EM for wild-
type C125S (six measurements) IL-2, 20.7±1.4 FM for M6 (four measurements),
25.3±6.1 tM for M1 (four measurements) and 3.3±0.6 RM for C1 (eight measurements).
2.2.3 KIT-225 cell proliferation assay
KIT-225 is a human IL-2 dependent T-cell line, expressing roughly 3000-7000IL-2Rapy
and 200000-300000 IL-2Ra (Arima et al., 1992; Hori et al., 1987). KIT-225 cells were
cultured in RPMI 1640 supplemented with 20 pM IL-2, 10% FBS, 200 mM L-glutamine,
50 units/mL penicillin and 50 gg/mL gentamycin.
KIT-225 cells were cultured in medium without IL-2 for six days. The cell culture
medium was changed after three days. On the sixth day, the cells were transferred into
medium containing wild-type IL-2 or IL-2 mutants at different concentrations at
105 cells/mL. Cell culture aliquots were taken at different times and the viable cell
density was determined using the Cell-titer GloTM (Promega) assay.
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2.2.4 Binding of IL-2 mutants to KIT-225 & YT2C2
KIT-225 cells were incubated (106 cells in 100 IL) with soluble IL-2 or mutants at 37 °C
for 30 minutes, at pH 7.4. Cells were washed with ice-cold PBS, pH 7.4, containing 0.1%
BSA and labeled with a biotinylated antibody against the FLAG epitope followed by
streptavidin-phycoerythrin on ice. Cells were washed again and mean single cell
fluorescence was determined using an EPICS-XL flow cytometer.
YT-2C2 is a human NK cell line expressing approximately 20000 IL-2ROy (Teshigawara
et al., 1987) . YT-2C2 cells were cultured in the same medium as KIT-225 cells, without
IL-2. YT-2C2 cells were incubated (106 cells in 100 FL) with the IL-2 mutants on ice for
30 minutes, at pH 7.4. Cells were washed with ice-cold PBS, (pH 7.4, 0.1% BSA) and
labeled with a biotinylated antibody against the FLAG epitope followed by streptavidin-
phycoerythrin on ice. Cells were washed again and mean single cell fluorescence was
determined using an EPICS-XL flow cytometer. The equilibrium dissociation constants
were determined using a global fit. 66% confidence intervals were calculated by as
described (Lakowicz, 1999).
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2.3 Results
2.3.1 Functional expression of IL-2 on the surface of yeast
Although IL-2 has been displayed on bacteriophage previously (Buchli et al., 1997),
directed evolution using phage display, to obtain IL-2 mutants with improved binding for
the IL-2R subunits has not been reported. IL-2 was expressed on the surface of yeast
cells, on the assumption that expression in a eukaryotic system would produce a higher
fraction of correctly folded protein. IL-2 was expressed as a fusion to the Aga2p
agglutinin subunit, on the surface of yeast (Boder and Wittrup, 1997). Expression of the
Aga2p-IL-2 fusion on the surface of yeast was measured by immunofluorescent labeling
of the c-myc epitope tag attached to the C-terminus of the Aga2p-IL-2 fusion
(Figure 2-1A). IL-2 displayed on the surface of yeast binds specifically to the soluble
ectodomain of IL-2Rct (Figure 2-1B), while negative control yeast displaying an
irrelevant scFv, D1.3, do not (Figure 2-1D). Presence of the c-myc tag indicates that the
full-length IL-2 fusion is displayed on the yeast cell surface. Figure 2-1C shows
immunofluorescent labeling of the c-myc tag on negative control yeast, displaying D1.3,
indicating the presence of D1.3 fusions on the yeast cell surface.
2.3.2 Screening of IL-2 library for clones with improved binding to IL-2Ra
A yeastdisplayed library of IL-2 mutants with a diversity of 5x106 clones was
constructed by error-prone PCR. This library was screened through four rounds of sorting
by flow cytometry, with regrowth and reinduction of surface expression between each
sort, to isolate clones with improved binding to soluble IL-2Ra. The ensemble of clones
after four rounds of sorting shows improved binding relative to wild-type IL-2 at 0.4 nM
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soluble IL-2Ra, normalized to the number of IL-2 fusions on the yeast surface by
labeling with mAb 12CA5 (Figure 2-2).
Twenty mutants were sequenced (Table 2-1), and seven distinct sequences were obtained
from the twenty clones sequenced. The most frequently occurring mutations (V69A and
Q74P) cluster in a region predicted to be at the IL-2/IL-2Ra interface, by a homology
model of IL-2 binding to its receptor subunits (Figure 2-3). Further, the mutant M6 has a
mutation I128T, which is close to the predicted IL-2/IL-2, and IL-2/IL-2Ry interface
(Bamborough et al., 1994; Berman et al., 2000).
2.3.3 Binding of IL-2 mutants to KIT-225 cells expressing a large excess of IL-2Ra
The IL-2 mutants isolated by yeast surface display were tested in soluble form for tighter
binding to IL-2Rca in its physiologically relevant context on the surface of KIT-225 cells.
Three different mutants were tested - M6 (V69A, Q74P, I128T), M1 (V69A, Q74P) and
C1 (I128T). We chose to test mutant M6 (and mutants derived from M6) due to the
observation that M6, and not the other six mutants, exhibited slightly improved biological
potency in preliminary KIT-225 cell proliferation assays (data not shown), described
subsequently. M1 represents the most frequently occurring two mutations. We
hypothesized, on the basis of the homology model of IL-2 binding to its receptor
subunits, that the subset of mutations in M6 represented by M1 would be sufficient for
increased binding affinity for IL-2Ra. C1 represents the mutation predicted to be close to
the IL-2/IL-2p and IL-2/IL-2Ry interface.
Figure 2-4 shows representative data for binding of M6, M1, C1 and wild-type (C125S)
IL-2 to KIT-225 cells, at 37 C. M6 and M1 have similar binding to KIT-225 cells, while
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C1 exhibits similar binding to wild-type (C125S) IL-2. Since the KIT-225 cells express a
large excess of IL-2Ra over IL-2RP and IL-2Ry, the binding data obtained corresponds
to IL-2Ra binding. Thus, M6 and M1 have a higher binding affinity for IL-2Ra on the
surface of KIT-225 cells, as compared to C1 and wild-type (C125S) IL-2. The
fluorescence data, in Figure 2-4, for concentrations 0.01 - 400 nM, were used to obtain a
gross estimate of the Kd for M6 and M1. An equation describing a simple one-step
binding equilibrium was used to fit the data.
Fobs= CLo ... (1)
d Lo
Where:
Fobs = observed fluorescence,
Lo = initial ligand concentration and,
C = proportionality constant.
The Kd for M6 and M1 can be estimated to be 1-2 nM (1.1±0.08 nM for M6 and 1.77±0.4
nM for M1). This represents roughly a fifteen to thirty-fold minimum improvement in
binding affinity, relative to a wild-type Kd value of 28 nM for C125A IL-2, a mutant with
alanine at position 125 (Liparoto et al., 2002). The errors represent variation due to the
error in estimating concentrations using quantitative western blotting. This calculation
underestimates the binding affinity than the actual value (overestimates the Kd) due to the
following systematic errors: 1) The cell density used in the binding assay represents
severe ligand (IL-2) depleting conditions. For equation (1) used above, to hold true, the
initial ligand concentration must be approximately equal to the free ligand concentration
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in solution at equilibrium. This assumption breaks down at concentrations less than
roughly 10 nM, for the experimental setup used, and the free ligand concentration is less
than the initial ligand concentration. This leads to an overestimate of the Kd (i.e. an
underestimate of binding affinity). 2) Internalization of ligand-bound receptors occurs at
37 C. The internalization rate of ligand-bound receptors can be assumed to be
proportional to the fraction of ligand-bound receptors, leading to an overestimate of the
Kd (underestimate of binding affinity).
The equilibrium dissociation constant (Kd) for C1 and C125S cannot be estimated from
this data, due to the rapid dissociation of IL-2Ra-bound IL-2 (Liparoto et al., 2002). The
receptor-bound IL-2 dissociates during the several wash steps involved in the experiment.
This leads to very low fluorescence signal, even at high concentrations for C1 and
C125S. M6 and M1 were also assayed for binding at these high concentrations for
consistency. Increase in fluorescence signal beyond 400 nM concentrations of M6 and
M1 may be due to binding to IL-2R[ and IL-2Ry on KIT225 cells and non-specific
binding at micromolar concentrations of M6 and Ml. In summary, the data in Figure 2-4
provides only a crude estimate of Kd, but definitively demonstrates that M1 and M6
exhibit substantial, qualitative improvements in binding affinity on the T cell surface,
relative to C125S and C1.
2.3.4 Binding of IL-2 mutants to YT-2C2 cells expressing IL-2RP and IL-2Ry
The binding of M1, M6 and C1 to YT-2C2 cells expressing IL-2R[ and IL-2Ry was
determined (Figure 2-5). A global fit was used to estimate the equilibrium dissociation
constants (Kd). These values are given in Table 2-2. The Kd values are consistent with
reported affinities for the binding of IL-2 to IL-2R3 (Liparoto et al., 2002). M1 was
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found to have a significantly lower binding affinity for IL-2RP[ than wild-type, M6 and
C1. This is interesting in light of Ml's mutation sites, predicted to be on the opposite
side from IL-2's contacts with IL-2R5P.
2.3.5 Proliferation of IL-2 dependent KIT-225 cells in response to IL-2 mutants
The proliferation of a T-cell line (KIT-225) in response to the IL-2 mutants was studied
to evaluate the effect of increase in affinity of IL-2 for IL-2Ra on biological potency. At
low concentrations (0.5 pM) and long times, C1 and M6 caused approximately 50-60%
greater proliferation of IL-2 dependent KIT-225 cells in cell culture, as compared to wild-
type (C125S) IL-2 and M1. The proliferation of KIT-225 cells in culture with the
different mutants, at different initial concentrations, is shown in Figure 2-6. It was
surprising to note that both M6 and C1 had slightly improved biological potency while
M1, with comparable affinity as M6 to IL-2Ra, did not. The observed increase in
affinity of IL-2 for IL-2Ra did not have appreciable effect on biological potency for
mutant M1 in this steady-state assay, suggesting that such an increase in affinity for
IL-2Rca alone is not responsible for the increased potency of M6.
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2.4 Discussion
We hypothesized that increasing the affinity of IL-2 for its alpha-receptor subunit would
create an IL-2 mutant with improved biological potency, for reasons described earlier
(Introduction). To this end, IL-2 mutants with improved affinity for IL-2Ra were selected
from a yeast-displayed randomly mutated library. The mutants obtained were tested for
proliferation of a T-cell line (KIT-225). The concentrations at which the KIT-225
proliferation assays were carried out lie in the picomolar range (0.5 - 5 pM), however the
equilibrium dissociation constants for the IL-2 mutants selected lie in the nanomolar
range. One of the predicted mechanisms for IL-2 mutants with increased IL-2Ra binding
affinity to have increased biological potency, is an increased concentration of IL-2
localized at the cell surface, by binding to IL-2Ra. Under the steady-state conditions of
the bioactivity assay, increase in occupancy of IL-2Ra would not be significantly
different for the mutants as compared to wild-type IL-2. The T-cell response to the IL-2
mutants is therefore not detectably different from wild-type IL-2. A greater increase in
occupancy of IL-Ra would conceivably lead to an increase in potency, through increase
in the local concentration of IL-2, at the cell surface. We hypothesize that a greater
difference in T-cell response, in these assays, may be observed for mutants with IL-2Ra
affinity in the picomolar range. However, on the basis of our results, we can conclude
that a fifteen to thirty-fold increase in affinity for IL-2Rct does not result in a
corresponding increase in biological potency, in proliferation assays at picomolar
concentrations, as described. The quantitative relationship between such steady-state,
low-concentration assays and the pharmacological situation in vivo is not clear however,
given the rapid renal clearance of parenterally administered IL-2.
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The mutations responsible for the higher affinity for IL-2Ra (V69A, Q74P) cause a
decrease in affinity for IL-2RP. One of the reasons for the decreased biological activity of
M1 relative to M6 may be this decrease in affinity for IL-2R3. We could not analyze the
effect of the selected mutations on the binding affinity for IL-2Ry due to the extremely
weak affinity of interaction between IL-2 and IL-2Ry (Liparoto et al., 2002).
M6 and C1 exhibit slightly improved biological potency relative to wild-type, in the T-
cell proliferation assays described. C1 has no appreciable change in affinity for IL-2Ra
and IL-2RfP, as compared to wild-type, while M1, with increased affinity for IL-2Ra, has
slightly decreased biological potency. Also, as explained earlier, there would not be a
significant increase in IL-2Ra receptor occupancy under the particular conditions of the
T-cell proliferation assays. These observations suggest that the increased potency of M6
in the T-cell proliferation assays is through a mechanism unrelated to the increase in
affinity for IL-2Ra. Previous studies have investigated the increased biological potency
of 2D 1, a mutant of IL-2. 2D 1 internalized by receptor-mediated endocytosis is recycled
to a greater extent than wild-type IL-2, leading to decreased depletion of 2D1 in cell
culture and hence improved biological potency (Fallon et al., 2000). Increased recycling
of internalized M6 and C1 could be a potential mechanism for increased biological
potency of M6 and C 1, relative to wild-type IL-2.
Our results establish the proof of concept of a strategy to isolate IL-2 mutants with
tailored binding characteristics and characterize T-cell response to these mutants. The
YT-2C2 cell-binding assay provides a convenient preliminary test to check and ensure
that the mutants selected do not have their affinities for IL-2RP greatly weakened. The
IL-2 mutants did not show increased potency in T-cell proliferation assays at low
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picomolar concentrations. Conversely, none of the seven isolated mutants showed loss of
biological potency as compared to wild-type IL-2, in preliminary assays (data not
shown). This work lays the foundation for the generation and characterization of IL-2
mutants with further improved affinities for IL-2Ra, sufficient to drive greater receptor
occupancy in the 0.1-10 pM concentration range. In addition, bioassays designed to
better mimic the transient nature of IL-2 exposure in vivo may highlight the altered
properties of these mutants.
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Table 2-1: Mutations in IL-2 clones with greater affinity for IL-2Ra compared to
C125S
Seven distinct sequences were obtained out of twenty clones sequenced.
Mutants IM161M1 3M121 M9 M5 IM301 M6
Isolates I 1 3 17 14 11 1 3
T
R
L
E
R I
D
R
D
A A A A A A
T
P P P P
R
H
A A
S
V
T
N
33
Position
1
11
46
48
49
61
64
68
69
71
74
79
90
101
103
114
128
133
WT aa
A
Q
M
K
K
E
K
E
V
N
Q
H
N
T
F
I
T
I
Table 2-2: Binding affinities of IL-2 mutants for IL-2R on YT-2C2 cells
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Kd (nM) 66% confidence intervals
WT (C125S) 94 70-135
C1 132 110-161
M6 210 149-331
M1 480 388-630
0PE fluorescence PE fluorescenceE fluor nce
PE fluorescence PE fluorescence
Figure 2-1: IL-2 is functionally displayed on the surface of yeast.
(A) Labeling of IL-2 displaying yeast with saturating concentration of anti-c-myc
antibody (9e10), (B) Labeling of IL-2 displaying yeast with 52 nM soluble IL-2R (C)
Labeling of D 1.3 (an irrelevant negative control scFv) displaying yeast with saturating
concentration of anti-c-myc antibody (9e10), (D) Labeling of D1.3 displaying yeast with
52 nM soluble IL-2Ra.
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Figure 2-2: Ensemble of clones with better binding for IL-2Ra compared to wild-
type C125S
Labeling with saturating concentration of anti-HA antibody(12CA5) and 0.4 nM
IL-2Ra (2x106 cells, 100 [L volume) at 37 °C. (A) Wild-type (C125S) (B) Population
isolated after four rounds of sorting.
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AS
Figure 2-3: Locations of mutations on a model of IL-2/receptor complex
IL-2 is shown in red, IL-2Ra subunit in blue, IL-2RP subunit in white, IL-2Ry subunit in
grey. The residues where mutations were encountered, in improved IL-2 mutants, are
marked - Q74 (orange), V69 (brown) and 1128 (green).
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Figure 2-4: Binding of solubly expressed IL-2 mutants to KIT-225 cells expressing
large excess of IL-2Ra, at 37 °C
Data shown is representative data from at least two experiments, for each mutant or
wild-type IL-2; the binding curves look similar at 4 °C (data not shown)
38
ItiV i .
10.75
0.50
0.25
0
1
8 0.75
8 0.50
- 0.25
IL 0
')
.N 1
E 0.75
0
Z 0.50
0.25
0
1
0.75
0.50
0.25
0
0.1 1 10 100 1000 10000
Concentration (nM)
Figure 2-5: Binding of solubly expressed IL-2 mutants to YT-2C2 cells expressing
IL-2R and IL-2Ry
Different symbols denote different data sets.
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Figure 2-6: Proliferation of IL-2 dependent KIT-225 cells in response to wild-type
(C125S) IL-2 and IL-2 mutants
(A) Number of viable KIT-225 cells in culture with time, at different concentrations
of wild-type (C125S) IL-2. Error bars indicate the standard deviation for three
separate cultures.
(B) Ratio of number of viable cells in culture with the mutants to number of cells in
culture with wild-type (C125S) IL-2. The concentrations are indicated on the
plots. Error bars indicate the standard deviation for three separate cultures.
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Chapter 3: IL-2 VARIANTS ENGINEERED FOR INCREASED
IL-2Ra AFFINITY EXHIBIT INCREASED POTENCY
ARISING FROM A CELL SURFACE LIGAND
RESERVOIR EFFECT
Proliferation of activated T cells and CD56 bright NK cells (Fehniger et al., 2002) caused
by interleukin-2 (IL-2) has been exploited in IL-2-based therapies for the treatment of
metastatic renal cell carcinoma and melanoma (Atkins et al., 1999; Fyfe et al., 1995).
Here we demonstrate the potentially improved therapeutic value of IL-2 variants
engineered to gain 15-30-fold increased affinity for the IL-2 alpha-receptor subunit
(IL-2Ra). A novel pulsed bioassay was used to more closely approximate the rapid
systemic clearance pharmacokinetics of cytokines such as IL-2, compared to
conventional static bioassays. In this assay, mutants with increased affinity for IL-2Ra
exhibit significantly increased activity for T-cell proliferation, whereas static bioassays
not only fail to reveal the increased activity resulting from enhanced IL-2Ra affinity
(false negatives), but also suggest improved activity for another mutant without enhanced
activity in the pulsed assay (false positive). Our studies on the mechanism leading to
increased activity of IL-2 mutants with increased IL-2Rca affinity suggest that cell-
surface IL-2Rct acts as a ligand reservoir for the IL-2 mutants. This leads to increased
cell-surface persistence of the IL-2 mutants with increased IL-2Ra affinity in cell-surface
ligand reservoirs and consequently increased integrated growth signal. Furthermore, a
mathematical model predicts increased persistence of cell-surface bound IL-2 in vivo for
enhanced IL-2Ra-binding IL-2 mutants, suggesting potentially improved therapeutic
value of allowing cellular capture of ligands in persistent cell-surface reservoirs. Finally,
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our findings emphasize the critical choice of appropriate bioassays to evaluate engineered
proteins and other drugs.
3.1 Introduction
Interleukin-2 is a potent immunomodulatory cytokine that acts on various immune cell
types. IL-2 based therapies exploit the proliferation of antigen-activated T cells and CD56
bright NK cells caused by IL-2 (Fehniger et al., 2002), for treatment of metastatic renal
cell carcinoma and melanoma (Atkins et al., 1999; Fyfe et al., 1995). When administered
intravenously, IL-2 is rapidly cleared from the body. IL-2 serum concentrations are in the
nanomolar range initially, and fall rapidly with a double exponential clearance rate with
half-lives of 12.9 and 85 minutes respectively (Konrad et al., 1990). Thus it is difficult to
maintain the therapeutically effective serum concentration range (1 - 100 pM) over a
sustained period of time. This narrow therapeutic window of effective concentration
coupled with rapid systemic clearance adversely affects IL-2 therapy.
The biological activity of IL-2 is mediated through the interaction of IL-2 with its multi-
subunit receptor (Nelson and Willerford, 1998). The IL-2 receptor system consists of the
alpha (IL-2Ra), beta (IL-2RP) and gamma (IL-2Ry) receptor subunits. IL-2Rat is not
involved in intracellular signaling, while IL-2R[ and IL-2Ry are necessary and sufficient
to mediate intracellular signaling. IL-2 binds with a very high affinity (Kd = 10-" M) to
the trimeric IL-2Rc3py complex, an intermediate affinity to IL-2RPy (Kd = 10-9 M) and
low affinity to the IL-2Ra subunit (Kd = 10-8 M). Antigen-activated T cells and CD56
bright NK cells, which mediate the therapeutically relevant effects of IL-2, express all
three receptor subunits and respond to picomolar concentrations of IL-2. However, at
42
nanomolar IL-2 concentrations, activation of the IL-2RPy on CD56 dim NK cells leads to
toxicity (Fehniger et al., 2002).
We hypothesized that increasing affinity of IL-2 for IL-2Ra would be a useful strategy to
construct IL-2 variants with potentially improved therapeutic properties. IL-2Ra is
overexpressed on the surface of activated T cells (Smith, 1989; Theze et al., 1996) and
has a long half-life (48 hrs) on the cell surface (Hemar and Dautry-Varsat, 1990). An
IL-2 mutant with increased affinity for IL-2Rca may bind to the surface of activated T
cells for a longer time and hence remain in circulation, captured on T cells, for much
longer than wild-type IL-2. Thus IL-2Ra on activated T cells may act as a reservoir for
IL-2 in circulation, leading to a prolonged persistence of IL-2 signaling. This should
enable reduced dosage and consequently lower toxicity. Yeast surface display and
directed evolution have been previously used to generate IL-2 mutants with increased
affinity for IL-2Rca (Rao et al., 2003). In this paper, we describe the bioassay evaluation
of such mutants in a novel pulsed bioassay assay that more closely approximates the
systemic clearance of IL-2 than conventional static bioassays. In this assay, a T cell line
shows significantly greater proliferation in response to IL-2 mutants with higher affinity
for IL-2Ra than wild-type IL-2 or a mutant with wild-type affinity for IL-2Ra. This
result not only demonstrates the increased activity of IL-2 mutants with increased IL-2Ra
affinity, but also emphasizes the pitfalls of false negatives and false positives arising from
an inappropriate choice of assay for evaluating the engineered IL-2 variants.
Conventional static bioassays at low picomolar concentrations suggested that increased
affinity of IL-2 for IL-2Ra did not exhibit a significant effect on the activity of the IL-2
mutants relative to wild-type IL-2 (Rao et al., 2003). Also, a mutant with no change in
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IL-2Ra affinity was implicated to have higher activity in the static assay, while the
pulsed bioassay shows no change in activity for this mutant.
We also investigated the mechanism conferring increased activity to IL-2 mutants with
increased affinity for IL-2Rct. Our results suggest that IL-2Ra on the T cell surface acts
as a ligand reservoir for IL-2 and mediates this increased activity for the IL-2 mutants.
Furthermore, a mathematical model predicts longer persistence of the IL-2 mutants with
increased affinity for IL-2Ra on the surface of T cells in circulation, when administered
as an intravenous (i.v.) bolus. This could conceivably lead to prolonged signaling from
the IL-2 mutants with increased affinity for IL-2Ra, even at low dosages, suggesting
potentially improved therapeutic value for these IL-2 mutants.
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3.2 Materials and Methods
3.2.1 IL-2 mutants
For clarity, the term "Interleukin-2" will be used throughout to refer to wild-type
Interleukin-2 and the Interleukin-2 mutants M6, M1, and C1. The wild-type IL-2
considered has a serine at position 125 (C125S - equivalent to Proleukin). Yeast
surface display and directed evolution were used to generate IL-2 mutants with increased
binding affinity for IL-2Ra (Rao et al., 2003). We considered three mutants - M6 (V69A,
Q74P, I128T), M1 (V69A, Q74P), and C1 (I128T). M6 and M1 have a fifteen-thirty fold
increased affinity for IL-2Ra as compared to wild-type IL-2. Mutant C1 has wild-type
affinity for IL-2Ra. The rationale behind the choice of these mutants for analysis has
been previously detailed (Rao et al., 2003).
Wild-type IL-2 and the IL-2 mutants were expressed solubly in a yeast expression
system, with an N-terminal FLAG epitope tag and a C-terminal c-myc epitope tag, as
previously described (Rao et al., 2003).
3.2.2 Conventional Static Bioassay
Proliferation of an IL-2 dependent cell line was used as a read-out to evaluate the activity
of the IL-2 mutants generated. KIT-225 is a human IL-2 dependent T-cell line, expressing
roughly 3000-7000IL-2Ralpy and 200000-300000 IL-2Ra (Arima et al., 1992; Hori et al.,
1987). A frozen stock of KIT-225 cells was created using cells cultured in a humidified
atmosphere with 5% CO2, at 37C, in RPMI 1640 supplemented with lnM IL-2, 10%
FBS, 200 mM L-glutamine, 50 units/mL penicillin and 50 g/mL gentamycin.
Subsequently, frozen aliquots were revived and cultured in medium containing 40 pM
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IL-2. Prior to the bioassay, KIT-225 cells were cultured in medium without IL-2 for one
day. Cells were then resuspended in medium containing wild-type IL-2 or IL-2 mutants at
different concentrations at 105 cells/mL. Cell culture aliquots were taken at different
times and the viable cell density was determined using the Cell-titer GloTM (Promega)
assay.
3.2.3 Pulse Bioassay
The pulse bioassay, where cells are exposed to IL-2 for a short period of time, was
designed as the simplest approximation for systemic clearance of IL-2. KIT225 cells were
starved in IL-2 free medium for one day. Cells were resuspended at 105 cells/mL in
medium containing wild-type IL-2, mutants or a negative control (no IL-2). After 30
minutes of incubation in a humidified atmosphere with 5% CO2, at 370 C, the cells were
centrifuged (8 minutes at 40 C) and the medium containing IL-2 was removed. Cells were
washed with medium without IL-2, at room temperature, and centrifuged again. The
supernatant was discarded and the cells were resuspended in medium without IL-2. The
cells were transferred to an incubator at 37°C containing a humidified atmosphere with
5% CO2. Cell culture aliquots were taken at different times and the viable cell density
was determined using the Cell-titer GloTM (Promega) assay.
3.2.4 Persistence of IL-2 on surface of KIT225 cells
The cell-surface associated IL-2 during the course of the pulse assay was determined
using flow cytometry. The protocol followed was exactly the same as described for the
pulse assay. KIT225 cells were pulsed with M6 or wild-type IL-2, at a concentration of
2 nM. At different time points after the final re-suspension step in medium without IL-2,
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cell culture aliquots were taken and centrifuged. Cells were resuspended in 100 LL
ice-cold PBS, pH 7.4, containing 0.1% BSA and a biotinylated antibody against the
FLAG epitope (Sigma). This was followed by incubation with streptavidin-phycoerythrin
on ice (Molecular Probes). Cells were centrifuged, the supernatant discarded, and
resuspended in ice-cold PBS, pH 7.4, containing 0.1% BSA. The mean single cell
fluorescence was determined using an EPICS-XL flow cytometer. The cell-surface bound
IL-2 may dissociate and re-bind after the final re-suspension step. To study this effect,
soluble human IL-2Rca (R&D Biosystems) at a concentration of 1 nM was used as a
capture reagent for any dissociated IL-2. This concentration represents a considerable
excess of soluble IL-2Rac molecules over the total cell-surface bound IL-2Ra in the
culture.
3.2.5 Mathematical model
A simple mathematical model was developed to describe the effect of increased affinity
of IL-2 mutants for the IL-2Ra subunit, on persistence of IL-2 on the cell surface, in the
context of systemic clearance of IL-2. The physical processes considered are
1) Systemic clearance of IL-2 from the body
2) Interaction of IL-2 with IL-2Ra on the cell surface
3) Endocytosis and degradation of IL-2Ra complexes
The differential equations governing the processes described are as follows:
d [IL - 2] = -A k, · [IL - 2] e-k ' - B' k2 [IL - 2] e-k' a +
(-k ' [IL - 2] ([a]o - [IL - 2 a]) + koff [IL - 2 -a] - k [IL - 2 -a]) Na
*--.(1)
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d [IL - 2a] = ko [IL-2] [a]o -[IL- 2a] (ko, [IL- 2]+ k + k) .(2)
The terms used and the parameter values chosen are described in Table 3-1. The
differential equations were solved using MATLAB.
The total number of IL-2Ra on the T-cell surface is assumed to remain constant. The
number of activated T cells in circulation is assumed to be 10% of the total T cells in
circulation and is an overestimate. This estimate is based on the CD25+ T cells in
circulation. The number of activated T cells is used to calculate molar concentrations of
cell-surface associated IL-2. Greater numbers of activated T cells would lead to an
increased contribution of depletion of IL-2 through endocytosis of
IL-2-IL-2Ra complexes. Thus we choose the number of activated T cells as 10% of the
total number of T cells in circulation, as a conservative estimate.
Endocytic degradation through IL-2Rafry is not considered. This simplification arises
primarily because there are far fewer (~100 fold lesser) IL-2Rapcy than IL-2Ra, on the
T-cell surface. The endocytic sink due to the IL-2-IL-2Rapy complexes under conditions
of maximal endocytic degradation was calculated and found to be negligible at times less
than 400 minutes. The details of this calculation are as follows:
All IL-2Rj3 and IL-2Ry subunits are assumed to be associated with the IL-2Ra subunit.
All IL-2Rapy trimers are assumed to be associated with IL-2. Maximal endocytic
degradation of IL-2-IL-2Rapy complexes will occur under these conditions. At steady
state the endocytic rate should equal the rate of synthesis of IL-2RaBy. The rate of
synthesis of IL-2Rapy can be estimated as (VR + kynC) (Fallon and Lauffenburger, 2000)
Where
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VR is the constitutive rate of IL-2Rabg synthesis and is 11/min
ksyn is the induced rate of IL-2Rabg synthesis and is 0.0011/min
C is the total number of IL-2-IL-2Rapy complexes. A value of 3000 is used as the
maximum estimate of IL-2-IL-2Rac4y complexes
The maximal endocytic degradation rate is thus estimated as 14/min/cell. Considering
108 cells/liter, this translates to a decrease of 2 femtomolar/min, in serum and cell surface
IL-2 concentration. After 400 min, this corresponds to a decrease in serum concentration
of IL-2 by 0.8 pM. At this time, the serum concentration of IL-2 is - 10 pM. Thus the
decrease in serum concentration of IL-2 due to endocytic degradation is negligible
relative to systemic clearance of IL-2. Also, at times less than 400 min, inclusion of the
endocytic degradation term in the model does not significantly alter the cell surface IL-2
concentration for wild-type IL-2 or the IL-2 mutants. Beyond this time, the maximal
endocytic rate considered affects the cell surface IL-2 concentration for wild-type IL-2
and the IL-2 mutants. Incidentally, the recommended dosing regimen for ProleukinTM
(wild-type IL-2) involves a 15 min. intravenous infusion every 8 hours (480 min).
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3.3 Results
3.3.1 A pulse assay approximates renal clearance
We earlier reported the generation of mutants with increased affinity for IL-2Ra (Rao et
al., 2003). Mutants M6 and M1 exhibit increased affinity for IL-2Ra while mutant C1
has wild-type IL-2Ra affinity. In static bioassays, in the 0.5-5 pM range of concentration,
M6 and C1 were found to have slightly increased activity relative to wild-type IL-2.
However, these concentrations represent severely ligand-depleting conditions since the
total number of IL-2Ra present on cell surfaces in the culture is greater than the number
of molecules of IL-2. To fully evaluate these mutants, we performed these assays under a
wider range of concentrations. Figure 3-1A shows the viable cell density, in response to
varying concentrations of wild-type IL-2 or the IL-2 mutants, assayed at 60 hours after
IL-2 addition. Consistent with previous results, we find that M6 and C1 have increased
activity relative to wild-type IL-2. M6 has an increased affinity for IL-2Ra, while C1 has
wild-type affinity. Thus, the observed slight increase in activity of M6 and C1 in this
bioassay is not attributable to increased affinity for IL-2Ra.
When administered as an i.v. bolus, IL-2 is rapidly cleared from the body, with half-lives
of 12.9 and 85 minutes (Konrad et al., 1990). Because the static assay does not reflect this
rapid clearance that occurs under physiological conditions, we designed a pulse assay to
crudely approximate systemic clearance. KIT225 cells were exposed to IL-2 for a period
of 30 minutes, then washed and resuspended in IL-2-free media, and the viable cell
density measured as a function of time. When exposed to 1 nM concentration of cytokine
for 30 minutes in the pulse assay, M6 and M1 showed significantly improved activity as
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compared to wild-type IL-2. C1 and wild-type IL-2 showed similar activity. This is
shown in Figure 3-1B.
We assayed the effect of varying the concentration of cytokine in the pulse assay on the
viable cell density. Figure 3-1C is a snapshot of viable cell density as a function of pulse
concentration, at 60 hrs after the cytokine pulse, while Figure 3-2 shows the effect viable
cell density in response to varying concentrations of wild-type IL-2 or the IL-2 mutants,
as a function of time. M6 and M1 show significantly higher activity than wild-type IL-2
and C1 over a broad pulse concentration range. Also, the level of proliferation obtained
using less than 100 pM pulse of mutants with higher affinity for IL-2Ra (M6 and M1)
cannot be achieved by using any concentration of C125S or Cl. It is interesting to note
that C1 and M6 show similar activity in a static assay (Figure 3-1A). A conventional
static bioassay would implicate C1 as a more active IL-2 variant than wild-type IL-2 and
M1. However C1 is likely to be ineffective in a physiological context, as suggested by a
pulse assay that more closely approximates systemic clearance. Conversely, M1 does not
show significantly improved activity in the static assay, but has similar activity as M6 in
the pulse assay. Thus, inappropriate assays can clearly lead to both false negatives and
false positives, demonstrating that the kinetic details of bioassay design are critical for
effective evaluation of protein variants with potentially improved therapeutic properties.
3.3.2 IL-2Ra acts as a ligand-reservoir in a pulse assay
We hypothesized that M6 and M1 exhibit increased activity in a pulse bioassay due to
increased persistence on the surface of KIT225 cells, with IL-2Ra acting as a reservoir
for IL-2 and promoting proliferation. To test this hypothesis, we used flow cytometry to
probe the cell-surface associated IL-2 as a function of time. As shown in figure 3-3A,
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surface-associated wild-type IL-2 is negligible after the wash steps in the pulse bioassay.
However, even after 6 hours, mutant M6 persists on the cell surface. The closed symbols
in Figure 3-2B show the kinetics of persistence of M6 on the surface of KIT225 cells.
Thus, the overexpressed IL-2Rca acts as a reservoir for IL-2 and mediates prolonged
signaling.
After the final wash step, when the cells are resuspended in IL-2-free medium, the
cell-surface bound IL-2 may dissociate and re-bind subsequently. We used soluble
IL-2Ra as a reagent to capture any dissociated IL-2, to detect any re-binding occurring in
the pulse assay. The cell surface associated M6 was probed using flow cytometry. As
shown by the open symbols in Figure 3-3B, there is greater decrease in cell-surface
bound IL-2, in the presence of the soluble IL-2Ra, indicating a certain amount of
re-binding of M6 in the pulse assay. The key observation, however, is that M6 persists on
the cell surface even in the presence of a capture agent IL-2Ra. In presence of soluble
IL-2Ra, a rapid initial decrease in cell-surface IL-2 followed by a slower rate of decrease
is observed. One explanation for these heterogeneous kinetics may be the presence of
complexes with both IL-2Ra and IL-2Rca species on the cell surface. This aspect of the
mechanism is currently under investigation. It should be pointed out that re-binding and
equilibration could also occur in the physiological context of systemic clearance, as is
evident from the mathematical model described below.
3.3.3 A mathematical model predicts potentially improved therapeutic value
IL-2Ra is overexpressed on the surface of antigen-activated T cells (Smith, 1989; Theze
et al., 1996) and has a long half-life on the cell surface (Hemar and Dautry-Varsat,
1990). Conceivably, an IL-2 variant that bound to IL-2Ra with a slow dissociation rate
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would remain in circulation, bound to IL-2Ra-overexpressing cells for a significantly
longer period than wild-type IL-2, even as serum IL-2 undergoes rapid systemic
clearance. We evaluated the effect of changing the dissociation rate of binding of IL-2 to
IL-2Ra in the context of systemic clearance of IL-2 with a mathematical model. The
model predicts significantly increased levels of cell-surface associated IL-2 and
significantly increased persistence of cell-surface bound IL-2, with as little as a ten-fold
decrease in the off-rate. Thus the model quantitatively confirms the concept of a cell
surface ligand-reservoir effect mediated by IL-2Ra. Prolonged elevated cell-surface
levels of IL-2 would lead to persistent signaling. A significantly reduced dose of the IL-2
mutants should therefore be sufficient to achieve the wild-type response, leading to
reduced toxicity and hence potentially improved therapeutic value. The greatly increased
activity of M6 and M1 in pulse assays is proof of concept for the improved therapeutic
potential of the class of IL-2 mutants with increased affinity for IL-2Ra.
The predicted free serum concentration levels of IL-2 are not significantly
different for the mutants with decreased dissociation rate of binding of IL-2 to IL-2Ra.
However the local concentration of IL-2 at the cell surface is very different for these
mutants, relative to wild-type IL-2. This is a conceptually distinct strategy compared to
conjugation of polyethylene glycol (PEGylation) to proteins, to increase their serum half-
life (Harris and Chess, 2003). PEGylation causes an increased serum concentration of
cytokine, but not necessarily increased cell-surface bound cytokine levels, as these are
governed by the affinity of the cytokine-receptor binding interaction. Furthermore,
PEG-ylated IL-2 remains available for interaction with NK cells in the circulation, with
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attendant side effects. By contrast, mutant IL-2 such as M1 or M6 are sequestered to the
surfaces of those cells specifically targeted for stimulation.
3.4 Discussion
We have demonstrated here that IL-2 mutants with enhanced IL-2Ra binding affinity
have significantly increased activity for proliferation of activated T cells overexpressing
IL-2Ra, through a cell-surface ligand-reservoir effect. A novel pulsed bioassay was
utilized to approximate the systemic clearance pharmacokinetics of IL-2. The IL-2
mutants exhibit increased activity in these assays, but not in conventional static
bioassays. Thus our results emphasize the critical nature of the choice of appropriate
bioassays to evaluate engineered protein variants.
We investigated the mechanism conferring increased activity to the IL-2 mutants with
enhanced IL-2Ra affinity. Our findings suggest that the overexpressed IL-2Ra on the T
cell surface acts as a ligand reservoir for the IL-2 mutants. This leads to increased cell-
surface persistence of the IL-2 mutants and hence increased integrated growth signal. Our
mathematical model predicts increased persistence of the IL-2 mutants in vivo, even at
low dosage concentrations. This suggests potential therapeutic value for the IL-2 mutants.
Also the lowered dosage concentration would help in the reducing the undesirable
inflammatory responses associated with the existing dosage concentration of IL-2. The
half-life of IL-2Ra on the antigen-activated T-cell surface is on the order of 48 hours
(Hemar and Dautry-Varsat, 1990). In the pulse assay, the half-life of M6, an IL-2 mutant
with 15-30 fold enhanced IL-2Rca affinity, on the surface of KIT225 cells is on the order
of 4 hours. This suggests that further substantial improvements in activity may be
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obtained by further decreasing the dissociation rate of interaction between IL-2 and
IL-2Ra.
It is interesting to note the striking similarity of cell surface retention of M6 with
interleukin-15 (IL-15) (Dubois et al., 2002). IL-2 and IL-15 share the IL-2RP and IL-2Ry
subunits while each have their own private alpha receptor subunit (Fehniger et al., 2002).
IL-15 has a high affinity for its private alpha receptor subunit, unlike wild-type IL-2. In
assays where the cytokine is withdrawn from the medium, IL-15 persists on the cell
surface for a long period of time, through association with IL-15Ra, and mediates
prolonged signaling (Dubois et al., 2002). M6, with increased affinity for the private
IL-2Ra subunit exhibits an increased persistence on the cell surface in similar assays.
Thus, our results support a possible role for the high affinity IL-15SRa as a capture
reagent to generate a ligand-reservoir, supporting previous work in this area.
The "cell surface reservoir" concept may be broadly applicable to numerous other
cytokine receptor systems with multi-subunit receptors, to generate super-agonists or
super-antagonists. Examples include interleukin-3 (IL-3), interleukin-5 (IL-5) and
Granulocyte Macrophage Colony Stimulating Factor (GM-CSF). IL-3, IL-5 and GM-CSF
use private alpha receptor subunits and a common beta subunit that is implicated in most
of the signaling associated with these cytokines (Guthridge et al., 1998). Cytokine
variants with increased affinity for their private alpha subunits would conceivably
increase persistence of these cytokines in circulation and hence lead to improved cytokine
super-agonists (through persistent signaling) or super-antagonists (through persistent
blocking of signaling). Thus cytokine variants with potentially improved therapeutic
effectiveness may be generated by this approach. However, as stated earlier, it is very
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important to use an appropriate in vitro bioassay to evaluate the activity of the cytokine
variants generated.
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Table 3-1: Description of terms used and parameter values chosen for the
mathematical model
Term Description Value Reference
[IL-2] Serum concentration of IL-2 (molar units) -
[IL-2.a] IL-2 in complex with IL-2Ra (molar units)
[a]0 Total IL-2Ra on T cell surface 100,000/cell
t Time (min) -
A Magnitude of fast component of double 0.866 (Konrad et al.,
exponential clearance 1990)
k, Rate constant for fast component of double 0.0537 min-' (Konrad et al.,
exponential clearance 1990)
B Magnitude of slow component of double 0.134 (Konrad et al.,
exponential clearance 1990)
k2 Rate constant for slow component of 0.00815 min' (Konrad et al.,
double exponential clearance 1990)
kon Association rate constant for IL-2-IL-2Ra 6e8 M-' min' (Liparoto et
interaction (wild-type) al., 2002)
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koff Dissociation rate constant for IL-2-IL-2R a 18 min-' (Liparoto et
interaction (wild-type) al., 2002)
kec Rate constant for endocytosis and 0.00024 min-' (Hemar and
degradation of IL-2/IL-2Ra complex Dautry-Varsat,
1990)
n Total number of activated T cells in 108 L' (Hodge et al.,
circulation 2000; Storek
et al., 2000)
Nay Avogadro number 6.023e23
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Figure 3-1: IL-2 mutants with higher affinity for IL-2Ra exhibit greatly increased
activity in a pulse assay, but not in a conventional steady-state proliferation assay
Error bars indicate standard deviation of triplicate measurements. Data shown is
representative of three separate experiments.
(A) Viable cell density as a function of IL-2 concentration, in a steady-state assay,
after 60 hrs.
(B) Viable cell density as a function of time, in a pulse-assay with an initial pulse
concentration of 1 nM IL-2.
(C) Viable cell density as a function of IL-2 concentration, in a pulse-assay, after
60 hrs.
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Figure 3-2: Viable cell density as a function of time, in a pulse assay, with varying
initial pulse concentrations of IL-2.
The pulse concentrations are as follows: A - 2 pM, B - 10 pM, C - 50 pM, D - 100 pM,
E - 500 pM, F- 2000 pM.
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Figure 3-3: IL-2Ra acts as a ligand-reservoir and mediates prolonged persistence of
M6 on the cell surface of KIT-225 cells relative to wild-type IL-2 (C125S)
PE fluorescence is a measure of cell-surface bound IL-2. Data shown is a representative
set of histograms for three different experiments
Different colored closed symbols denote data from different experiments where no
capture reagent is present. Different colored open symbols denote data from different
experiments where soluble IL-2Ra was used as a capture reagent for dissociated M6.
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Figure 3-4: Model for persistence of IL-2 mutants with decreased off-rate for
IL-2Ra on activated T cells, in blood circulation.
Decreased off-rate of IL-2 mutants for IL-2Ra results in greater levels and longer
persistence of IL-2 on activated T cells in blood circulation.
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Chapter 4: IL-2 MUTANTS WITH PICOMOLAR IL-2Ra
BINDING AFFINITY STIMULATE GROWTH
RESPONSES QUANTITATIVELY EQUIVALENT TO
IL-15
Several alternative mechanisms have been proposed to explain the contrasting effects of
IL-2 and IL-15 on T cell proliferation and death. We have used directed evolution to
construct IL-2 mutants that bind IL-2Ra with affinities comparable to the IL-15/IL-1SRa
interaction. These IL-2 mutants exhibit T cell growth response/receptor occupancy
curves indistinguishable from that for IL-15, suggesting that much of the difference
between the IL-2 and IL-15 effects arise simply from their 1,000-fold differing affinities
for their private alpha receptor subunits. T cells proliferate for up to six days following a
30-minute incubation with these IL-2 mutants, which may lead to potential applications
for cancer & viral immunotherapy.
4.1 Introduction
Interleukin-2 (IL-2) and Interleukin-15 (IL-15) can exert qualitatively differing effects on
T cells (Fehniger et al., 2002; Waldmann, 2002; Waldmann et al., 2001) - for example,
IL-2 promotes Activation Induced Cell Death (AICD) while IL-15 inhibits AICD.
Transgenic mice lacking the IL-2 alpha receptor subunit (IL-2Ra) exhibit T cell
expansion and autoimmune disease (Willerford et al., 1995), while IL-15 alpha receptor
subunit (IL-15Ra) null transgenic mice have reduced numbers of CD8* T cells and other
lymphocytes (Lodolce et al., 1998). However, paradoxically, both IL-2 and IL-15 signal
through the same IL-2R3 and IL-2Ry receptor subunits. The mechanisms leading to
different biological effects of IL-2 and IL-15 are poorly understood. IL-2 and IL-15
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mediate their biological response through a trimeric receptor consisting of shared beta
and gamma subunits and a private alpha receptor subunit (Fehniger and Caligiuri, 2001;
Nelson and Willerford, 1998). IL-15Ra is expressed in a broad range of cells and tissues,
by contrast with IL-2Ra, whose overexpression is in general limited to activated
mononuclear cells (Kobayashi et al., 2000). For cells simultaneously expressing the alpha
receptor subunit for both IL-2 and IL-15, there are marked differences in the growth
response to IL-2 and IL-15 (Dubois et al., 2002). Evidence from fluorescence resonant
energy transfer (Damjanovich et al., 1997) and antibodies binding IL-2RPi at different
epitopes (Lehours et al., 2000) suggest that the IL-15/IL-2R13/IL-2Ry complex differs
topologically from IL-2/IL-2Rr/IL-2Ry, and consequently may trigger qualitatively
different signals. It has also been proposed that the small cytoplasmic portion of IL- 1 5RRa
may be involved in signaling, by contrast with IL-2Ra (Bulanova et al., 2001). Further
evidence for qualitative differences in signaling between IL-2 and IL-15 is that IL-15-
mediated proliferation is inhibited to a greater extent than IL-2 by rapamycin inhibition of
FKBP (Dubois et al., 2003).
We hypothesize that a major contributor to differences between IL-2 and IL-15 is simply
altered cell-surface receptor occupancy, driven by differing alpha subunit binding
affinities. Both IL-2 and IL-15 bind the IL-2RPy heterodimeric receptor with similar
affinity (Kd 1 nM) and can signal through IL-2/15R[y in the absence of the private
alpha receptor subunit. However, they differ starkly in their binding to their private alpha
receptor subunits. IL-15 has a very high binding affinity for IL-15Ra (Kd ~10 pM), while
IL-2 binds with low affinity to IL-2Rca (Kd - 10 nM) (Fehniger and Caligiuri, 2001).
This leads to prolonged persistence of IL-15 but not IL-2 on the surface of T cells, in in
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vitro assays where cytokine is withdrawn from the medium (Dubois et al., 2002). Here
we have generated IL-2 mutants with picomolar IL-2Ra binding affinity by directed
evolution, and find that the T cell proliferative response to these mutant IL-2 species is
essentially the same as responses to equivalent receptor occupancies for IL-15. These
results support the hypothesis that IL-2R[/IL-2Ry receptor occupancy is a primary
determinant of growth responses for both IL-2 and IL-15.
4.2 Results and Discussion
IL-2 mutants with a range of affinities for IL-2Ra that approach the affinity of IL-15 for
IL-1 5Ra (Table 4-1, Figure 4-1) were generated using yeast surface display and directed
evolution (Rao et al., 2003). We compared the bioactivity of high IL-2Ra affinity IL-2
mutants with IL-15 in a T cell line (Fl5R-Kit) expressing both IL-2Ra and IL-15Ra
subunits, in addition to IL-2R and IL-2Ry. Pulse bioassays, where cells are incubated in
cytokine for only a short period of time, were used to mimic the transient cytokine
exposure history typical of bolus pharmacokinetics (Rao et al., 2004). Our objective was
to quantitatively analyze the relationships between receptor occupancy and proliferation
response for IL-2, IL-15, and a series of IL-2 mutants bridging the
three-order-of-magnitude gap between them in alpha receptor subunit binding affinity.
In pulse assays, IL- 15 persists on the cell surface for over two days, while wild-type IL-2
has negligible persistence on the cell surface (Figure 4-2A), consistent with previous
results (Dubois et al., 2002). IL-2 mutants with increased IL-2Ra affinity however, have
greatly increased persistence on the cell surface relative to wild-type IL-2 (Figure 4-
2B, C, D), since IL-2Ra acts as a ligand reservoir for high IL-2Ra affinity IL-2 mutants.
65
Artifactual binding of these IL-2 mutants to IL-15Ra was excluded by the observation
that excess IL-15 does not diminish surface labeling by these mutants (data not shown).
Increased initial private alpha receptor occupancy after cytokine withdrawal leads to
increased cell surface persistence of cytokine over the course of several days (Figure 4-
3). The increased persistence of high IL-2Ra affinity IL-2 mutants is likely a result of
both decreased dissociation of the mutants from cell surface IL-2Ra and more efficient
recycling of the mutants to the cell surface following internalization, since high
IL-2Raaffinity IL-2 mutants also have improved binding at endosomal pH (data not
shown) and conceivably recycle to a greater extent than wild-type IL-2 (Fallon et al.,
2000). For a given initial receptor occupancy, IL-15 exhibits somewhat greater
persistence than the IL-2 mutants (Figure 4-2, 4-3). This may be due to a significantly
lesser sensitivity of the IL-15/IL-15Ra binding interaction to lowered pH relative to the
binding of IL-2 mutants to IL-2Ra, and consequently more efficient endocytic recycling
to the surface following internalization (Figure 4-4).
We compared the T cell growth response mediated by IL-15 and high IL-2Ra affinity
IL-2 mutants in a pulse assay to explore the relationship between cell surface persistence
and bioactivity. Consistent with previous observations (Dubois et al., 2002), IL-15
promotes the growth of T cells in a pulse assay, unlike wild-type IL-2 (Figure 4-5). An
insignificant level of wild-type IL-2 is associated with IL-2Ra on the cell-surface
following pulse exposure, whereas IL-15 persists in IL-ISRa ligand reservoirs on the cell
surface for a prolonged period of time (Figure 4-2A). Mutants with increasing IL-2Ra
binding affinity exhibit prolonged cell surface persistence (Figure 4-2B-D) and also
stimulate increased growth of T cells (Figure 4-5). Picomolar concentrations of several
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IL-2 mutants stimulate T cell growth for up to six days following a 30-minute pulse
exposure, while even nanomolar pulse concentrations of wild-type IL-2 fail to produce
any net proliferation.
The relationship between T cell growth response and initial receptor occupancy after
cytokine withdrawal was quantitatively examined (Figure 4-6A,B). Maximum viable cell
density attained and the integral of viable cell number over a ten-day period were used as
metrics to quantify the family of growth response curves shown in Figure 4-5. The
integral of cell viability as well as the maximum cell number correlate linearly with the
number of interleukin molecules initially captured in cell surface receptor reservoirs
(Figure 4-6A, B), demonstrating the existence of a single pharmacodynamic dose-
response curve relating growth to initial receptor occupancy for IL-2, IL- 15, and all of the
six IL-2 mutants.
IL-2 induced T cell growth is consistent with a quantal signal transduction hypothesis
(Smith, 1989), by which once the signal mediated through IL-2Raiy exceeds a certain
threshold, growth occurs at a specific growth rate independent of the magnitude of the
growth signal. The concept of threshold signaling complex levels governing cell fate
decisions has additionally found applicability in stem cell biology more broadly (Zandstra
et al., 2000). For an IL-2 (or IL-15) dependent T cell line such as F15R-Kit, a similar
threshold response also converts an actively growing T cell culture to a death phase once
the IL-2Rapy signal is depleted below a certain level. In order to compare the responses
to different mutants and different pulse concentrations on a common basis, each growth
curve was normalized by its maximum viable cell density (Figure 4-7) and then aligned
on the time axis such that the peak cell number occur at an approximately common time
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(Figure 4-8). All of the IL-2 wild-type and mutant growth curves from Figure 4-5 map
by this procedure onto a single universal growth curve, indicating that the specific growth
and death rates are indeed approximately constant (Figure 4-6C). Consequently, the
amount of time spent in the growth phase is sufficient to completely characterize the
growth curves in Figure 4-5. In other words, the growth curves in Figure 2 can be
reconstructed from the universal growth curve (Figure 4-6C) once the initial time (time of
cytokine withdrawal) is mapped on to the universal growth curve by aligning the time for
transition from the growth phase to the death phase, presumed to occur upon depletion of
IL-2Rapy signal below a threshold signal value. This time shift correlates strongly with
initial receptor occupancy, with growth maintained for up to six days at the highest
occupancies achieved with the IL-2 mutants (Figure 4-9). The growth kinetics of IL-15
are also described by a universal growth curve (Figure 4-6D), although with somewhat
slower death rates than the IL-2 mutants, possibly due to prolonged signaling due to
increased persistence of IL-15 relative to any of the IL-2 mutants (Figure 4-2A vs. 4-2B-
D). The very similar universal growth curves for IL-2 and IL-15 (Figure 4-6C,D) further
reinforce the functional equivalence of the pharmacodynamic proliferative response
mediated by IL-15 and the high IL-2Ra affinity IL-2 mutants at equivalent receptor
occupancies.
We establish here a quantitative relationship between receptor alpha subunit binding
affinity and mitogenic activity for IL-2 and IL-15. Cell surface IL-15Ra, with high
affinity for IL-15, acts as a capture reagent for IL-15 that retains IL-15 on the cell surface
for a prolonged period of time and mediates growth of T cells expressing IL-
15Ra (Dubois et al., 2002). IL-2Ra acts as a similar cell surface ligand reservoir for IL-2
68
mutants with increased affinity for IL-2Ra. Our results strongly suggest that a primary
difference in biological activity between wild-type IL-2 and IL-15 results from their
different affinities for their respective private alpha receptor subunit.
Lymphocyte homeostasis is maintained in vivo by a balance between signals from
lymphotrophic survival factors and apoptotic death pathways (Khaled and Durum, 2002).
Numerous cytokines with central roles in controlling the number of cells in the lymphoid
compartment signal through the common gamma (yc) subunit of the IL-2R: IL-2, IL-4,
IL-7, IL-9, IL-15, and IL-21, indicating a broad and central role for the growth and anti-
apoptotic signal provided by IL-2Ry,. It has been hypothesized that differences in the
effects of IL-4 and IL-7 relative to IL-2 and IL-15 are a result of altered receptor
expression on different cell types, rather than qualitatively distinct intracellular signaling
pathways (Marrack and Kappler, 2004), and our results are consistent with this view.
The general approach of creating a cell-bound ligand reservoir might enable engineering
of mutant cytokines with enhanced potency for GM-CSF, IL-3, and IL-5 (Guthridge et
al., 1998) , since they also possess non-signaling alpha capture receptor subunits.
The IL-15-like behavior of high IL-2Ra affinity IL-2 mutants has potentially significant
implications for IL-2 based cancer immunotherapy. IL-2 is FDA-approved for the
treatment of metastatic renal cell carcinoma and melanoma (Atkins et al., 1999; Fyfe et
al., 1995). At nanomolar concentrations, wild-type IL-2 mediates deleterious toxic
effects, through IL-2RPy on CD56 dim NK cells (Fehniger et al., 2002). The increased
potency of high IL-2Ra affinity IL-2 mutants relative to wild-type IL-2 should allow the
use of reduced doses, with consequently lower toxicity. The use of IL-15 to replace IL-2
in cancer immunotherapy has been suggested due to the inhibitory effects of IL-15 on
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AICD (Waldmann et al., 2001), however the broad tissue distribution of IL-15Ra might
conceivably lead to detrimental side effects (Fehniger and Caligiuri, 2001). IL-2Ra is
expressed by activated T cells, and so high IL-2Rca affinity IL-2 mutants should mediate
a biological response selectively in these desired target cells. Thus the IL-2 mutants
described here may combine the specificity of wild-type IL-2 with the desired
immunotherapeutic effects of IL-15.
4.3 Materials and Methods
4.3.1 Generation of IL-2 mutants
Human IL-2 with a cysteine to serine mutation at position 125 (C125S) was considered as
wild-type IL-2 (equivalent to Proleukin'). A previously described protocol (Rao et al.,
2003) was used to express wild-type IL-2 as an Aga2p protein fusion in the EBY100
strain of yeast Saccharomyces cerevesiae. A library of approximately 107 yeast-displayed
IL-2 mutants (termed "library A") was generated as previously described (Rao et al.,
2003).
A soluble, biotinylated form of the ectodomain of human IL-2Ra was a kind gift of
Dr. T. L. Ciardelli (Dartmouth Medical School, Hanover, NH). An equilibrium binding
screen, as previously described (Rao et al., 2003), was used to isolate IL-2 mutants with
increased binding affinity for soluble IL-2Ra. WC9 and WE3 are two of the clones with
improved IL-2Ra binding affinity isolated after two rounds of sorting by flow cytometry.
After one round of sorting library A, DNA from the pool of mutants isolated was
extracted using the Zymoprep kit (Zymo Research Corporation). The mutant IL-2 coding
sequences in this pool of DNA were amplified by PCR (termed "reaction 1").
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Concurrently, the mutant IL-2 coding sequences were subjected to random mutagenesis
by error-prone PCR in the presence of nucleotide analogs 8-oxodGTP and dPTP to
control mutagenesis rates, as previously described (Rao et al., 2003). The product
obtained in this mutagenic PCR was amplified further by PCR (termed "reaction 2") in
the absence of the nucleotide analogs. The products from the reactions 1 and 2 were
mixed in a 1:1 ratio and DNA shuffling (Stemmer, 1994) was carried out on the
combined pool of DNA. The final PCR product after DNA shuffling was used to generate
a library of approximately 1.5x108 yeast-displayed IL-2 mutants (termed "library B"),
using the protocol described previously (Rao et al., 2003). IL-2 mutants with decreased
dissociation rate of binding (off-rate) to soluble IL-2Rawere isolated from library B
using a kinetic screen (Boder and Wittrup, 2000) with wild-type IL-2 (Chiron) as soluble
competitor. la-1, 2-4 and lb-8 are three of the clones with slower IL-2Rabinding off-
rate isolated after four rounds of sorting by flow cytometry.
WC9, WE3, la-l, 2-4, lb-8 and M6, a previously reported IL-2 mutant (Rao et al., 2004;
Rao et al., 2003), were chosen in particular for detailed evaluation since they have a
range of IL-2Ra binding affinities that bridge the three-order-of-magnitude gap in private
alpha receptor subunit binding affinity between wild-type IL-2 and IL-15. Wild-type IL-2
and the IL-2 mutants were expressed solubly in yeast, with an N-terminal FLAG epitope
tag and a C-terminal c-myc epitope tag. FLAG immunoaffinity chromatography (Sigma)
followed by size exclusion chromatography on a SuperdexTM 200 column (Pharmacia
Biotech) was used to purify the proteins. The protein concentrations were measured using
the Micro BCA Protein Assay (Pierce).
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4.3.2 Tissue Culture
F15R-Kit cells were a kind gift of Dr. T. A. Waldmann (National Cancer Institute, NIH,
MD). F15R-Kit is an IL-2 dependent human T cell line with stable overexpression of
human IL-15Ra and IL-2Ra (Arima et al., 1992; Dubois et al., 2002; Hori et al., 1987).
These cells also express IL-2RP and IL-2Ry (less than 10,000 copies per cell), though at
much lesser levels than IL-2Ra and IL-15Ra (_ 105-106 copies per cell). The IL-15Ra
expressed in F15R-Kit cells has an extracellular N-terminal FLAG epitope tag. Cells
were cultured in a humidified atmosphere with 5% CO2, in RPMI 1640 supplemented
with 0.5 nM IL-2, 10% FBS, 1 mM sodium pyruvate, 200 mM L-glutamine and 0.8 g/L
geneticin. Prior to any assay, cells were cultured in medium without IL-2 for one day.
4.3.3 Quantifying alpha receptor number on cells
Cell surface IL-2Rca was detected using a mouse monoclonal antibody against human
IL-2Ra conjugated with R-Phycoerythrin (PE) (Pharmingen). Cell surface IL-15Ra has
an N-terminal FLAG epitope tag and was detected by immunofluorescent staining with a
mouse monoclonal antibody M2 (Sigma) against the FLAG epitope along with a goat
anti-mouse antibody conjugated with PE (Molecular Probes/Sigma). Cell surface bound
IL-15 was detected using a mouse monoclonal antibody MAB247 (R&D Biosystems)
against IL-15 along with a goat anti-mouse antibody conjugated with PE. Quantum
Simply CellularTM microbeads (Sigma) were used to quantify the total number of IL-2Ra,
IL-15Ra or cell surface bound IL-15 molecules on F15R-Kit cells, using the
manufacturer's protocol. Briefly, the microbeads and the cells were subjected to identical
immunofluorescent staining using antibodies to detect IL-2Ra, IL-15Ra or cell surface
bound IL- 15. The median fluorescence values of distinct microbead populations that bind
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to known, incremental amounts of mouse immunoglobulin were used to generate a
standard curve. The median fluorescence value of the cells labeled to detect IL-2Ra,
IL-1S5R or cell surface bound IL-15 was used with the appropriate standard curve to
determine the number of cell surface alpha receptor or bound IL-15 in antigen binding
capacity (ABC) units.
4.3.4 Binding Assays
F15R-Kit cells were labeled (- 100,000 cells/mL) with varying concentrations of soluble
wild-type IL-2, IL-2 mutants or IL-15 (R&D Biosystems) for 30 minutes at 37 °C and
pH 7.4. It should be noted that because the cells are metabolically active under these
conditions, endocytic trafficking could perturb the estimate of the binding constant Kd;
however, this procedure provides a more accurate estimate for cell-surface interleukin
levels in the proliferation experiments performed at 37C than titrations on ice. The cells
were subsequently labeled with a polyclonal anti-c-myc chicken antibody (Molecular
Probes) followed by a goat-anti-chicken antibody conjugated with Alexa dye (Molecular
Probes) on ice, to detect cell-surface-bound wild-type or mutant IL-2. Alternately, the
cells were labeled with mouse monoclonal antibody MAB247 against IL-15 followed by
a goat-anti-mouse antibody conjugated with PE on ice, to detect cell-surface-bound IL-
15. The median single cell fluorescence was determined using an EPICS-XL flow
cytometer. Due to the vast overexpression of IL-2Ra and IL-1SRa (_ 105-106 copies per
cell) relative to IL-2RP and IL-2Ry (less than 10,000 copies per cell) (Arima et al., 1992;
Hori et al., 1987) on F15R-Kit cells, the fluorescent signal from cell-surface bound
cytokine can be assumed to be entirely due to binding to the alpha receptor subunit.
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4.3.5 Estimation of Kd
Equilibrium dissociation constants for binding of wild-type and mutant IL-2 and IL-15 to
their respective private alpha receptor subunit were determined using the equation:
c Lo
Kd +Lo
Where:
Fobs = Observed background-corrected median fluorescence
Lo = Concentration of wild-type or mutant IL-2 or IL-15 used
c = proportionality constant
Data from two separate experiments were used to determine the Kd values for wild-type
and mutant IL-2 and IL-15. For each protein, one global Kd value and a proportionality
constant c for each experiment were used in a global data fit procedure. The maximum
median fluorescence observed at saturating concentrations of wild-type or mutant IL-2,
corresponding to saturation of all cell surface IL-2Ra, should be the same. Therefore, the
value of c was constrained to be the same for wild-type IL-2 and the IL-2 mutants for
each experiment. Even though the complete binding isotherm is not captured in the
concentration range considered for wild-type IL-2 and some of the IL-2 mutants, the
constraint on c allows a Kd value to be estimated for each IL-2 species. 66% confidence
intervals were determined using the procedure described in (Lakowicz, 1999).
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4.3.6 Persistence Assays
A pulse bioassay, as previously described (Rao et al., 2004), was carried out on F15R-Kit
cells with a 100 pM pulse concentration of wild-type IL-2, IL-2 mutants or IL-15.
Briefly, cells were exposed to a 30-minute pulse of cytokine and then washed with and
resuspended in cytokine-free medium. At different time points after cytokine withdrawal,
cell-surface associated ligand was determined using immunofluorescent staining (as
described earlier) and flow cytometry.
4.3.7 Bioassays
A pulse bioassay is the simplest approximation for bolus pharmacokinetics. Pulse
bioassays, as previously described (Rao et al., 2004), were carried out on F15R-Kit cells
with varying pulse concentrations of wild-type IL-2, IL-2 mutants or IL-15. The viable
cell density was determined over a ten-day period using the Cell-titer GloTM (Promega)
assay. IL-2Ra and IL-15Rc numbers on the cell surface were determined for the cells
used in the pulse bioassay.
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Table 1: IL-2 mutants with increased IL-2Ra binding affinity.
F15R-Kit cells expressing IL-2Ra and IL-1SRa were labeled with wild-type IL-2, IL-2
mutants or IL-15 for 30 minutes at 370 C and pH 7.4. Cell surface bound protein was
measured using flow cytometry. Data from two different experiments (Figure 4-1) were
used to estimate Kd values as described (materials and methods).
Protein Mutations Kd (pM) 66% Confidence
Intervals
C125S (WT) 30030 ND
WC9 S4P, T1OA, Q 11R, V69A, Q74P, 1585 950-2700
N88D, T133A
M6 V69A, Q74P, I128T 1215 740-2000
WE3 N30S, V69A, Q74P, I128T 778 400-1270
lb-8 K8R, Q13R, N26D, N30T, K35R, 409 230-690
T37R, V69A, Q74P, I92T
la-I N30S, E68D, V69A, N71A, 254 150-420
Q74P, S75P, K76R, N90H
2-4 N29S, Y31H, K35R, T37A, 180 110-300
K48E, V69A, N71R, Q74P,
N88D, I89V
IL-15 76 52-110
ND - not determined
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Figure 4-1: Binding of wild-type and mutant IL-2 to IL-2Ra and IL-15 and IL-15Ra
Different symbols denote different data sets. Solid lines denote the estimated bound
fraction using the best-fit value of Kd. The Kd values estimated reasonably predict the
fraction of alpha receptors bound at a given concentration of wild-type or mutant IL-2 or
IL-15.
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Figure 4-2: Cell surface persistence of wild-type IL-2, IL-2 mutants and IL-15
F15R-Kit cells (~100,000 cells/mL) expressing IL-2Ra and IL-15Ra were labeled with
100 pM wild-type IL-2, IL-2 mutants or IL-15 for 30 minutes at 37°C and pH 7.4. Cells
were then washed with and resuspended in cytokine-free medium. Cell surface bound
protein was measured using flow cytometry at different time points following cytokine
withdrawal. The initial (time zero) value corresponds to the cell-surface bound ligand
before the wash step. The median fluorescence value for 2-4 at time zero was used to
normalize the data for wild-type IL-2 and IL-2 mutants for each data set. The median
fluorescence value for IL-15 at time zero was used to normalize data for IL-15, for the
data set denoted by open circles. For the IL-15 data set denoted by open squares, the Kd
value for IL-15 (Table 4-1) and the experimentally determined total number of IL-15Rca
were used to estimate the number of IL-15-bound IL-15Ra at time zero. The number of
IL-15-bound IL-15Ra on the cell surface was directly determined for subsequent time
points. The number of IL-15-bound IL- 15Ra at time zero was used to normalize this data
set. Normalized values less than 0.001 are plotted as 0.001.
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Figure 4-3: Persistence on cell surface correlates strongly with initial receptor
occupancy
The area under the curve of a plot of cell-surface-bound interleukin versus time
(Figure 4-2) serves as a quantitative measure of the exposure history of the cells to
surface bound ligand i.e. persistence and was estimated using trapezoidal rule. The Kd
values for 2-4 and IL-15 and total numbers of cell surface IL-2Ra or IL-15Ra were used
to estimate the initial number of 2-4-bound IL-2Ra and IL-15-bound IL-1SRa. The
product of normalized cell surface bound wild-type or mutant IL-2 (Figure 4-2) and the
initial number of 2-4-bound IL-2Ra at time zero was used as an estimate of the number
of wild-type or mutant IL-2-bound IL-2Ra on the cell surface.
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Figure 4-4: IL-15 binding to IL-15SRa is less sensitive to lowered pH than 2-4
binding to IL-2Ra
Binding of both 2-4 and IL-15 to their respective alpha receptor subunits is decreased at
pH 5 (relative to pH 7.5). However, the degree of decrease in binding at pH 5 (relative to
pH 7.5) is significantly greater for 2-4 than IL-15. The significantly lesser sensitivity of
IL-15 binding to IL-15Ra at endosomal pH is consistent with IL-15 recycling to a much
greater extent than the IL-2 mutants, leading to increased persistence for a given initial
receptor occupancy. F15R-Kit cells were cultured in medium without IL-2 for 1-2 days
prior to the assay. Cells were labeled with 50, 100 or 500 pM of 2-4 or IL-15, at pH 7.5
or pH 5, for 30 minutes at 37 °C. Single cell fluorescence was determined by flow
cytometry. For each concentration, the ratio of background-corrected median
fluorescence at pH 5 to the value at pH 7.5 was calculated. Error bars denote standard
deviation of three separate experiments.
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Figure 4-5: IL-2 mutants and IL-15, but not wild-type IL-2, stimulate T cell growth
F15R-Kit cells ( 100,000 cells/mL) expressing IL-2Ra and IL-15Ra were incubated
with a range of concentrations of wild-type IL-2, IL-2 mutants or IL- 15 for 30 minutes at
37°C and pH 7.4. Cells were then washed with and resuspended in cytokine-free medium.
Viable cell number over a ten-day period was determined using the Cell Titer-GloTM
(Promega) luminescence assay.
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Figure 4-6: Pharmacodynamic response of IL-2 mutants and IL-15 is equivalent
(A and B) Growth response of 15R-Kit cells as quantified by the integral of viable cell
density over a ten-day period and the maximum cell density linearly correlates with initial
receptor occupancy for wild-type IL-2, IL-2 mutants and IL-15. Although the logarithm
of surface interleukin is plotted to condense the three-log dynamic range, the relationship
is well represented by linear regression with the correlation coefficient R2 shown. The
total numbers of IL-2Raand IL-15Ra were determined experimentally. The initial
receptor occupancy was estimated using Kd values and the total receptor number. X-error
bars represent error in estimating initial receptor occupancy due to error in Kd value
estimates. Y-error bars represent standard deviation of triplicate measurements. (C) The
growth kinetics of wild-type IL-2 and all IL-2 mutants, for all concentrations, is described
by one universal growth curve (D) IL-15 follows an essentially similar universal growth
curve as IL-2
82
A
AA It
AtA A
D A
i i i i
, -- R
rI. A~N Wr
10.8
0.6
0.4
0.2
0
4-0,,Cla
LI0
co
.5
CU
0
z
1
0.8
0.6
0.4
0.2
0
1
0.8
0.6
0.4
0.2
0
0 2 4 6 8 10
0 2 4 6 8 10
Time (days)
Figure 4-7: Normalized T cell growth responses
The growth curves (Figure 4-5) for wild-type IL-2 and IL-2 mutants were normalized by
the maximum viable cell density for each concentration
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Figure 4-8: Normalized and time-shifted T cell growth responses
The normalized growth curves (Figure 4-7) were shifted on the time axis such that the
viable cell density extrapolates to zero after at least 14 days. The value of 14 days was
arbitrarily chosen because the viable cell density for T cell cultures treated with 1 nM 2-4
(highest concentration used for the IL-2 mutant with highest IL-2Ra binding affinity)
extrapolates to zero after 14 days.
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Figure 4-9: The magnitude of shift on time axis correlates strongly with initial
receptor occupancy
Experimentally determined total IL-2Ra numbers and Kd values were used to determine
the initial number of IL-2Rc bound with wild-type or mutant IL-2, following cytokine
withdrawal. The X-error bars denote the error in estimating the initial bound IL-2Ra due
to error in Kd estimates.
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Chapter 5: CONCLUSIONS
The primary objective of the research presented in this thesis was to generate IL-2
mutants with potentially improved therapeutic value. We used existing data in the
literature to formulate a strategy for engineering improved IL-2 variants. On the basis of
qualitative considerations and mathematical modeling, we hypothesized that IL-2 variants
with increased binding affinity for the alpha receptor subunit of IL-2 will have potentially
improved therapeutic value. Yeast surface display and directed evolution were used to
generate IL-2 mutants with increased IL-2Ra affinity. In novel pulsed bioassays designed
to mimic bolus pharmacokinetics, these mutants exhibit significantly increased potency
for T cell proliferation relative to wild-type IL-2. Conventional bioassays not only fail to
reveal the increased potency resulting from enhanced IL-2Ra affinity (false negatives),
but also suggest improved potency for a mutant without enhanced activity in the pulsed
bioassay (false positive). Our results underscore the critical nature of the choice of
appropriate bioassays to evaluate engineered proteins and other drugs.
Cell surface IL-2Ra acts as a ligand reservoir for the mutants with increased IL-2Ra
affinity, leading to increased persistence of the mutants on the cell surface and
subsequently increased growth signal. This is analogous to the prolonged persistence of
IL-15, which binds with high affinity to IL-15Ra, on cell surface IL-15Ra reservoirs. We
have shown that T cell growth responses mediated by the high affinity IL-2Ra mutants
are quantitatively equivalent to those mediated by IL-15. Our results suggest that the
contrasting effects of IL-2 and IL-15 on T cells in vivo is largely due to the 1,000-fold
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different affinities of wild-type IL-2 and IL-15 for their respective private alpha receptor
subunits. The major contributions of this thesis can be summarized as follows:
1) IL-2 mutants with potentially improved therapeutic value were generated.
2) The cell surface ligand reservoir mechanism leading to increased potency of the
IL-2 mutants was elucidated.
3) A novel bioassay was designed to mimic bolus pharmacokinetics. Our results
show that the choice of appropriate bioassays is critical for the evaluation of
engineered proteins.
4) A quantitative relationship between binding affinity for the private alpha receptor
subunit and T cell growth response that is valid for both IL-2 and IL-15 was
established. The quantitative functional equivalence of high IL-2Ra affinity IL-2
mutants and IL-15 suggests that much of the difference between IL-2 and IL-15
stems from their vastly different affinities for their respective alpha receptor
subunit.
The work described in this thesis lays the foundation for the development of IL-2 variant
based improved IL-2 therapies. The next step involves the evaluation of the IL-2 mutants
in proliferation and toxicity assays using human peripheral blood mononuclear cells
(PBMC). Secretion of pro-inflammatory cytokines by CD56 dim NK cells in response to
the IL-2 mutants can be used as a measure of toxicity. The IL-2 mutants were engineered
for increased binding to human IL-2Ra. Increased affinity for IL-2Ra mediates increased
persistence of the IL-2 mutants on cell surface IL-2Ra reservoirs and subsequently
increased T cell growth response. These mutants do not exhibit improved binding to
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murine IL-2Rca (data not shown) and conceivably will not lead to increased murine T cell
proliferation. Therefore, in vivo tests on mice should be conducted on transgenic mice
with human IL-2Ra. In general, prior to any animal testing, the increased binding of the
IL-2 mutants to IL-2Ra expressed by the animal should be verified.
The IL-2 mutants can be used to better understand any differences in signaling mediated
by IL-2 and IL-15. An interesting question would be if indeed distinct intracellular
signaling pathways are involved in the signaling mediated by wild-type IL-2, the IL-2
mutants and IL- 15.
The general approach of creating a cell-bound ligand reservoir, exploited in the case of
IL-2, might also enable engineering of mutants with enhanced potency for GM-CSF,
IL-3, and IL-5 (Guthridge et al., 1998) , since they also possess non-signaling alpha
capture receptor subunits.
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ADDITIONAL EXPERIMENTS
A.1 IL-2 mutants do not perceptibly bind to IL-15Ra
Protocol
KIT225 cells over-expressing IL-2Ra and IL-15Ra were labeled with the IL-2 mutants
with and without saturating amounts of IL-15. A decrease of IL-2 binding signal in the
presence of IL-15 would indicate binding of IL-2 mutants to IL-15Rca
Results
Experiment 1:
KIT225 cells were labeled with wild-type IL-2 (C125S) or IL-2 mutants at 1 nM
concentration, with or without the presence of 2 nM IL-15. Cell surface bound IL-2 was
detected.
As shown in Figure A- 1, The binding of IL-2 to KIT225 cells is not perceptibly affected
by the presence of saturating amounts of IL-15. This suggests that the IL-2 mutants do
not perceptibly bind IL-1SRa.
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Figure A-1: Presence of IL-15 does not perceptibly affect binding of IL-2 to KIT225
cells Black curves denote binding of IL-2 (1 nM) to KIT225 cells in absence of IL-15
Red curves denote binding of IL-2 in the presence of 2 nM IL- 15
Experiment 2:
At different concentrations of 2-4, there is no perceptible effect of the presence of
saturating amounts of IL-15, on the binding of 2-4 to KIT225 cells (Figure A-2). This
suggests that 2-4 does not perceptibly bind IL- 15Ra. (Note that for the 500 pM the
distributions are not the same and therefore cannot be compared accurately)
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Figure A-2: Presence of IL-15 does not perceptibly affect binding of 2-4 to KIT225
cells at various concentrations
Black curves denote binding of 2-4 to KIT225 cells in absence of IL-15
Red curves denote binding of 2-4 in the presence of 2 nM IL-15
Experiment 3:
The IL- 1 5Ra on KIT225 cells has an N-terminal FLAG tag. KIT225 cells were labeled
with 2-4 ( nM) and an anti-FLAG antibody (M2) with and without saturating amounts of
IL-15. 2-4 also has an N-terminal FLAG tag. Therefore, the M2 binding signal comes
from M2 bound to 2-4 and M2 bound to IL-15Ra.
In the presence of IL-15, there is a decrease in M2 signal indicating that IL-15 blocks the
binding of M2 to IL15Ra, at least partially. However, there is no perceptible decrease in
the binding of 2-4 to KIT225 cells in the presence of IL- 15. This suggests that 2-4 does
not perceptibly bind IL-15Ra. This is shown in Figure A-3
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Figure A-3: Presence of IL-15 does not perceptibly affect binding of 2-4 to KIT225
cells but blocks M2 binding to IL-15Ra
Black curves denote binding of 2-4 (1 nM) and M2 to KIT225 cells in absence of IL-15
Red curves denote binding of 2-4 (1 nM) and M2 in the presence of 2 nM IL- 15
Notes
The experimental system used is not the optimal system to prove that IL-2 does not bind
IL- 15Ra. IL- 15Ra are roughly half in number relative to IL-2Ra. Thus the maximum
decrease in signal in the presence of IL-15 is approximately 33%. On a logarithmic scale
this is a fairly small change.
Nevertheless, at 1 nM (the maximum IL-2 concentration used in our bioassays) there is
no perceptible change in signal (over noise which is typically 10%) as indicated by the
overlay plots
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A.2 Effect of acid strip on cell surface ligand reservoir
Protocol
KIT225 cells were subjected to an acid strip procedure as follows. Cells were washed
once with ice-cold PBS and twice with acid strip solution (10 mM citrate, 0.14 M NaC1,
50 mg/mL BSA, pH 2.8).
Cells were subjected to an acid strip before incubation with 2-4 in the pulse assay or after
incubation with 2-4. Cells subjected to an acid strip, but incubated in medium without
IL-2 during the pulse assay were used as a negative control. Cell surface bound 2-4 after
the acid strip was determined using flow cytometry. Only cells with the same forward
scatter - side scatter profile as the control cells (without acid strip) were considered. The
viable cell number after three days was measured using the Promega Cell Titer-Glo
luminescence bioassay.
Results
Acid strip causes decrease in cell viability
Cells subjected to the acid strip procedure have less than 10% viability, relative to
control cells.
No acid strip With acid strip
Figure A-4: Acid strip causes decrease in cell viability
Error bars indicate standard deviation of triplicate measurements.
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* Acid strip removes cell surface bound 2-4
The acid strip procedure completely removes cell surface bound 2-4, as shown in
Figure A-5
1oo
FL1 LOG
Figure A-5: Acid strip removes cell surface bound 2-4
The shaded green histogram is the negative control. Red histogram represents cells
labeled with 2-4 after the acid strip. The blue histogram represents cells subjected to the
acid strip after incubation with 2-4 in the pulse bioassay
* Cell surface bound 2-4 leads to increased proliferation
Cells subjected to the acid strip procedure prior to incubation with 2-4 in the pulse
assay show increased proliferation relative to a negative control. Cells where 2-4 is
stripped from the cell surface after the pulse assay do not undergo proliferation. This
indicates that the cell surface bound ligand mediates cell proliferation in the pulse
bioassay (Figure A-6).
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Figure A-6: Cell surface bound ligand mediates cell proliferation in the pulse assay
PA - acid strip prior to incubation with ligand in pulse assay
A - acid strip prior to incubation with ligand in pulse assay
Error bars indicate standard deviation of triplicate measurements
Notes:
Histograms in Figure A-6 were obtained using less than 1000 cells. This is because most
of the cells were affected by the acid strip procedure used.
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APPENDIX B: MATLAB CODES
Main program
clear all;
i = 1000; % initial concentration in pM
n = le8; % cells per liter
Nav = 6.023e23; % Avagadro number
koffl = 18; % off rates in min-1
koff2 = 1.8;
koff3 = 0.18
options = [ ];
xO = [i 0];
[tl,x] = ode23s(@odeset, [0 1000], xO,
ial = n/Nav*x(:,2)*1e12;
[t2,x] = ode23s(@odeset, [0 1000], xO,
ia2 = n/Nav*x(:,2)*1e12;
[t3,x] = ode23s(@odeset, [0 1000], xO,
ia3 = n/Nav*x(:,2)*1e12;
options,i,n,koff1);
options,i,n,koffl );
 options,i,n,koffl);
Function
function dx = odeset(t,x,i,n,koff 1);
%define all parameters
konl = 6e8; % association rate M-1 min-1
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APPENDIX B: IMATLAB CODES
kecl = 0.00024; % endocytic rate min-1
aO = 100000; % receptors/cell
kl = 0.693/12.9; % min-1 alpha clearance from blood
k2 = 0.693/85; % min-1 beta clearance from blood
Nav = 6.023e23; % Avagadro no.
% xl = IL-2
% x2 = IL-2-a
% i = initial IL-2 concentration (pM)
dx = zeros(2,1);
dx(1)=-kl *(0.866*i*exp(-k1 *t))-(0.1 34*i*exp(-k2*t))*k2 - kon1 *x(1 )*(aO-x(2))*n/Nav
+ koff1 *x(2)*n/Nav*1 e12 - kecl *x(2)*n/Nav*le12;
dx(2)=kon1 *x(1)*l e-12*aO - x(2)*(kon1 *x(1)*1 e-12+koff1 +kecl);
%
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